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ABSTRACT 
CCAAT/enhancer-binding protein (C/EBP) transcription factors play essential roles in gene 
regulation. The lung-enriched isoform C/EBPα is known to inhibit proliferation, promote 
differentiation and stimulate gene expression characteristic of the mature differentiated 
pulmonary epithelium. C/EBPβ, also enriched in the lung, plays a role in cell differentiation and 
the regulation of inflammatory and host defense genes in several organs. The activity of 
C/EBPβ is decreased in smokers with chronic obstructive pulmonary disease (COPD), 
indicating a role in COPD pathogenesis. The objective of this thesis was to investigate the 
unique or overlapping roles of C/EBPα and C/EBPβ in lung epithelial differentiation, and to 
assess the contribution of C/EBPβ in regulating pulmonary inflammation. 
 
To investigate unique vs. overlapping roles of C/EBPα and C/EBPβ in the lung, the pulmonary 
phenotype of mice lacking C/EBPα (CebpaΔLE mice), C/EBPβ (CebpbΔLE mice) or both 
C/EBPα and C/EBPβ (CebpaΔLE; CebpbΔLE mice) specifically in the lung epithelium, all 
generated by SFTPC-Cre mediated excision, was investigated. Cell culture experiments 
suggested that C/EBP and C/EBP bind the same elements within a lung-specific promoter, 
and that their functions are partially overlapping. Pre-natal CebpaΔLE mice and CebpaΔLE; 
CebpbΔLE mice displayed immature lungs similar to the lungs of premature infants, and 
CebpaΔLE; CebpbΔLE mice exhibited even more impaired airway epithelial cell differentiation 
than the CebpaΔLE mice. The proportion of CebpaΔLE mice that survived and reached adulthood 
spontaneously developed a majority of the histopathological hallmarks of COPD, possibly 
caused by infiltrating inflammatory cells – similar to what is observed in COPD and what is 
mechanistically proposed to drive COPD pathogenesis. These findings are indicative of a 
relationship between immature lungs at birth, C/EBPs and the development of inflammatory 
lung disease.  
 
Considering the previous documentation of decreased airway epithelial C/EBPβ activity in 
smokers with COPD, C/EBPβ could have a role in COPD pathogenesis. The role of C/EBPβ in 
regulating inflammatory and innate immune responses in the lung was on this account 
investigated by employing a translational approach encompassing clinical samples as well as in 
vitro and in vivo experiments. CEBPB was significantly down-regulated in the airway 
epithelium of both current and former smokers compared to never-smokers, and in cigarette 
smoke extract-treated primary human airway epithelial cells in vitro, suggesting that C/EBPβ 
plays a role in smoking-induced disease. Supporting this, inhibition of CEBPB in human airway 
cells in vitro resulted in a compromised inflammatory response to smoke. Moreover, cigarette 
smoke-exposed CebpbΔLE mice displayed reduced respiratory neutrophilia and induction of 
inflammatory mediators, including the neutrophil chemoattractant Groa, compared to smoke-
exposed controls. LPS-challenged CebpbΔLE mice also exhibited blunted respiratory 
neutrophilia and lower pulmonary expression of Groa, compared to LPS-challenged control 
littermates. In addition, suppression of LPS-induced neutrophilia and inflammatory gene 
expression by formoterol, a long acting β2-adrenoceptor agonist used in treatment of COPD, 
was impaired in CebpbΔLE mice. C/EBP transactivation was increased by treatment with 
formoterol in vitro, possibly through a β2-adrenoceptor and cAMP-dependent mechanism. This 
demonstrates that both inflammatory as well as anti-inflammatory stimuli involve regulation of 
gene transcription by C/EBPβ. 
 
Taken together, these findings demonstrate that C/EBPα and C/EBPβ play pivotal and partly 
overlapping roles in airway epithelial differentiation, and that C/EBP and the lung epithelium 
orchestrates inflammatory responses as well as anti-inflammatory signaling by β2-adrenoceptor 
agonists in the lung. Thus, C/EBPs may influence tissue regeneration in lung homeostasis and 
disease as well as inflammatory and anti-inflammatory signaling, and are potential contributors 
to COPD pathogenesis. 
 
 
  
POPULÄRVETENSKAPLIG SAMMANFATTNING 
Transkriptionsfaktorer är proteiner som binder till reglerande element i gener och kontrollerar 
cellens genuttryck. CCAAT/enhancer-binding proteiner, C/EBP:er, är högt uttryckta 
transkriptionsfaktorer som är betydelsefulla för en rad vitala cellulära processer. C/EBPα, som 
är anrikad i lungan, bidrar till att stoppa celldelning och stimulerar samtidigt utmognad av de 
specialiserade celler som är karaktäristiska för den fullt utvecklade lungan. En annan C/EBP 
faktor som är högt uttryckt i lungan, C/EBPβ, spelar också en viktig roll för cellers utmognad, 
och har dessutom föreslagits vara viktig för reglering av inflammatoriska och 
immunförsvarsgener. Förmågan hos C/EBPβ att binda till DNA och därmed aktivera geners 
uttryck är lägre hos rökare med kronisk obstruktiv lungsjukdom (KOL), men inte hos rökare 
utan luftvägssymptom, vilket antyder att C/EBPβ skulle kunna bidra till sjukdomsutvecklingen. 
KOL är en långsamt förlöpande lungsjukdom orsakad av de inflammatoriska processer som 
tobaksrökning framkallar, och utmärks av en minskad lungfunktion. Sjukdomsprocessen 
omfattar inflammation och förträngning av lungans små luftvägar (bronkiolit), samt 
nedbrytning (emfysem) av de små lungblåsorna som ansvarar för gasutbyte i lungan 
(alveolerna). Dessutom ses förändringar av luftvägsepitelet, där en ökning av antalet 
slemproducerade celler är karakteristisk. Målet med denna avhandling var att undersöka 
funktionerna av C/EBPα och C/EBPβ i utmognaden av luftvägsepitelet, och utreda ifall 
C/EBPβ bidrar till luftvägsinflammation och hämning av denna inflammation, vilket kan ha 
implikationer för sjukdomsprocesser och behandlingsstrategier i KOL.  
   
Initiala cellförsök antydde att C/EBPα och C/EBPβ binder till samma genreglerande DNA-
element, och att dessa transkriptionsfaktorer har delvis överlappande roller. I likhet med 
förtidigt födda barn, som ofta drabbas av akut andnöd och behöver andningsstöd, uppvisar möss 
som saknar C/EBPα specifikt i lungans epitel omogna lungor. Hos möss som saknar både 
C/EBPα och C/EBPβ i lungans epitel är lungorna än mer underutvecklade och utmärks av 
bristfällig utmognad av luftvägsepitelet samt ökat antal slemproducerande celler, i likhet med 
patologin i inflammatoriska luftvägssjukdomar. Dessutom utvecklar vuxna möss som saknar 
C/EBPα spontant en majoritet av de lungvävnadsförändringar som är karakärisktiska för KOL. 
Dessa patologiska förändringar skulle kunna förklaras av den inflammatoriska bild mössen 
uppvisar, liknande den inflammation som orsakar och driver KOL. Detta antyder ett 
orsaksförhållande mellan omogna lungor vid födeln, C/EBP-faktorer och utvecklingen av 
inflammatorisk obstruktiv lungsjukdom senare i livet. Stora kliniska studier som undersöker 
förekomsten av lungfunktionsnedsättning och luftvägsobstruktion hos vuxna individer som fötts 
för tidigt är därför av stort intresse. Större kunskap inom detta område kan förbättra 
behandlingsmetoderna av förtidigt födda barn, och därmed minska riskerna för dessa individer 
att utveckla luftvägsobstuktion senare i livet.  
 
Eftersom C/EBPβ potentiellt skulle kunna bidra till insjuknandet och sjukdomsförloppet i KOL 
undersöktes den roll C/EBPβ spelar i luftvägsinflammation. Genuttrycket av C/EBPβ är lägre i 
luftvägsepitelet hos rökare, jämfört med icke-rökare, samt i odlade epitelceller som exponerats 
för cigarettrök. Dessutom är den inflammatoriska reaktionen mot cigarettrök försvagad i 
epitelceller med inhiberat uttryck av C/EBPβ, samt i möss som saknar C/EBPβ i lungans epitel. 
Detta stödjer att C/EBPβ i lungans epitel bidrar till de inflammatoriska processer som vållas av 
cigarettrökning, vilka betraktas som centrala i sjukdomsbilden i KOL. Bevarade 
immunreaktioner är emellertid viktiga för att bekämpa luftvägsinfektioner, som är ofta 
förekommande bland patienter med KOL och anses accelerera sjukdomsförloppet. Möss som 
saknar C/EBPβ i lungans epitel har mycket riktigt ett dämpat inflammatoriskt svar mot 
bakteriekomponenten endotoxin, vilket antyder att försvaret mot bakterieinfektioner är nedsatt i 
dessa möss. β2-agonister används rutinmässigt i behandlingen av inflammatorisk lungsjukdom, 
såsom KOL. Dessa läkemedel verkar luftrörsvidgande, men har även inflammationshämmande 
effekter. Dock är de positiva effekterna av inhalerade β2-agonister relativt små bland KOL 
patienter. I likhet med detta var hämningen av luftvägsinflammation med β2-agonister utebliven 
i möss som saknar C/EBPβ. Ytterligare försök visade att och β2-agonister ökar inbindning av 
  
C/EBP-faktorer till DNA, som potentiellt skulle kunna hämma luftvägsinflammation. Den 
minskade DNA-bindande aktiviteten av C/EBPβ hos rökare med KOL skulle därför kunna 
förklara den ringa anti-inflammatoriska effekten av inhalerade β2-agonister, samt den ökade 
känslighet mot luftvägsinfektioner, som föreligger vid denna sjukdom.  
 
Tillsammans visar resultaten i den här avhandlingen att C/EBP-faktorer är betydelsefulla för 
utmognaden av luftvägsepitelet och att C/EBP bidrar till inflammation såväl som hämning av 
inflammatoriska processer i lungan. C/EBP:er kan således påverka immunförsvar samt 
regenerering av luftvägsepitelet i olika inflammatoriska sjukdomstillstånd, och är potentiellt 
bidragande faktorer i utvecklingen av KOL. Ökade kunskaper om C/EBP-faktorer kan öka 
förståelsen kring sjukdomen KOL och därmed också bidra till bättre behandlingmöjligheter för 
denna utsatta patientgrupp. 
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1 INTRODUCTION 
 
 
1.1 THE LUNG AND AIRWAYS 
 
The mammalian lung and airways consist of a series of morphologically distinct cell 
types with unique functions, and include cells of epithelial, lymphoid, vascular, 
muscular as well as nervous origin. The main function of the respiratory system is to 
facilitate gas exchange and supply the circulatory system with oxygen, at the same time 
as carbon dioxide is removed from the bloodstream. The lung epithelium plays a 
central role in maintaining the conduit for air to and from the lung parenchyma, as well 
as in facilitating gas exchange in the alveoli. The surface epithelium lining the airways 
also serves as a first line of defense against invading pathogens, as it is the site of initial 
contact for both environmental and inflammatory stimuli [1, 2]. More specifically, the 
airway epithelium attracts and activates inflammatory cells, clears inhaled agents but 
also regulates lung fluid balance and smooth muscle cell activity.  
 
The proximal part of the airways consists of the trachea, bronchi and bronchioles, while 
respiratory bronchioles constitute the distal airways (Figure 1). In the human lung, the 
respiratory bronchioles represent an extensive zone of transition ranging between the 
most distal part of the conducting airways (i.e. the terminal bronchioles) and the 
alveoli. In contrast, this zone is completely absent in the murine airways. The airway 
wall of the respiratory bronchioles are interrupted by alveolar outpockets, which in 
similarity to the alveolar sacs of the acinus mediate gas exchange [3].  
 
 
 
 
Figure 1. The human respiratory tree. The trachea divides into the main stem bronchi and subsequently 
several generations of bronchi. These in turn give rise to regular, conducting, terminal and respiratory 
bronchioles, the former part of the conducting airways and the latter part of the respiratory airways.  
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1.1.1 Lung development 
 
Lung formation is divided into five structural periods: embryonic initiation, and the 
pseudoglandular, canalicular, saccular and alveolar stages. These periods are all shared 
between species, although temporal and regional diversities exist [4]. During lung 
organogenesis, the respiratory epithelium distal to the trachea grows and divides, and 
gives rise to the bronchi, bronchioles as well as the alveolar ducts [3]. In total, the 
respiratory tree consists of between 221 and 223 branches in the adult human lung. Our 
understanding of branching morphogenesis has been significantly advanced by studies 
in Drosophila melanogaster, as well as the assessment of these processes in mice [5, 6]. 
Also, extensive documentation of different signaling molecules and transcription 
factors involved in lung developmental processes exist from animal models. Of note, 
many of these signaling pathways are implicated in pathological conditions in the adult 
lung [7].  
 
Embryonic stage/Initiation 
At approximately day 28 (week 3) in humans and embryonic day (E)9.5 in mice, the 
establishment of localized NK2 homeobox (NKX)2-1 expression in the foregut 
endoderm induces the formation of two primary lung buds that evaginate into the 
visceral mesenchyme [8, 9]. Removal of the visceral mesenchyme blocks lung growth 
and branching morphogenesis [10], which confirms that paracrine signaling between 
mesenchymal cells surrounding the endodermally-derived tube is crucial for lung 
organogenesis, as originally proposed by Alescio and colleagues in 1962 [11]. This 
intricate signaling includes sonic hedgehog (SHH) in the pulmonary epithelium and 
fibroblast growth factors (FGFs) in the surrounding mesenchyme, which are crucial for 
early lung development [6, 7, 12]. As the embryonic stage of lung development 
continues, the major bronchi are formed and septation of the tracheal-esophageal tube 
occurs.  
 
Pseudoglandular stage 
The subsequent step in lung development, the pseudoglandular period, occurs between 
week 5-17 in humans and from E11.5 to E16.5 in mice. Stereotypic branching and 
budding, a repetitive process of endbud invasion into the mesenchyme, peaks in the 
pseudoglandular period and is a hallmark of this stage [6, 10, 12, 13]. Data obtained 
from the developing mouse lung has been used to generate a complete map of 
branching morphogenesis, reveling a highly complex and strictly controlled pattern of 
branching [5]. The temporal-spatial expression pattern and cooperative function of gene 
regulating proteins represent the principal mechanisms by which branching 
morphogenesis is controlled, and are hence of particular importance for lung 
development. NKX2-1, expressed in epithelial cells of the dividing lung bud in the 
pseudoglandular period, is together with signaling molecules and gene regulating 
proteins such as transforming growth factor (TGF)β, FGFs and GATA binding proteins 
(GATAs) putatively central in lung branching morphogenesis [5, 9, 10, 12-14]. In 
addition, CCAAT/enhancer-binding proteins (C/EBPs) are first detected at the end of 
the pseudoglandular period (around E15.5 in mice), and these transcription factors are 
also implicated in lung development [15].  
 
The general lung structure is well-established by E16.5 in mice. Furthermore, the 
mesenchyme surrounding the budding epithelium forms blood vessels by 
vasculogenesis, smooth muscle cells are first detected and innervation of the lung 
   3 
begins in this stage [6, 10]. Although the structure of the airways is established by the 
end of the pseudoglandular period, the epithelial cells lining the airways are relatively 
undifferentiated before the canalicular stage. As discussed in further detail below, 
autocrine-paracrine and cell-cell interactions are vital in epithelial cell differentiation 
and lung maturation [10].  
 
The canalicular stage 
In the canalicular period, week 16-26 in humans and E16.5-17.5 in mice, peripheral 
branching morphogenesis continues and the respiratory bronchioles appear in the 
human airways. In addition, the vascular bed develops, innervation continues and the 
pulmonary acinus forms [4, 10]. Capillaries are arranged to surround the airspaces, with 
many sites of close contact with the cuboidal epithelium. Thus, the formation of the 
blood-air barrier starts in the canalicular period, as differentiation of type I 
pneumocytes begins [4, 16]. An important role for forkhead box (FOX) proteins and 
reduced paracrine SHH signaling has been proposed in many of the processes in the 
canalicular stage of lung development, specifically in lung maturation and cellular 
differentiation [17].  
 
The saccular and alveolar stage 
Differentiation of the epithelium is a key feature of the saccular stage, between week 
24-38 in humans and E17.5-postnatal day (P)5 in mice [4, 10]. In this period of lung 
development, the peripheral airways dilate and the lung saccules are increasingly 
vascularized. Also, in the beginning of this period, production and secretion of 
surfactant is initiated, a process that is associated with the differentiated epithelium. 
Thus, the saccular period is a crucial step in lung development, in which the lung is 
prepared for the first breath [10]. In line with this, the beginning of the saccular period 
currently represents the limit of viability for premature births [4]. As in the previous 
canalicular stage, an important role for C/EBPα has been demonstrated for lung 
maturation in this stage [15, 18-20].  
 
In the final, alveolar stage of lung development, week 38 to maturity in humans and P5-
P28 in mice, the alveoli grow and septate, and the maturation of the pulmonary 
vasculature continues [4, 10].  
 
Table 1 
Histological stages of lung development 
Stage Week (humans) Day (mice)  Process 
Embryonic w3 - w5 E9.5 - E11.5 Budding 
Psudoglandular w5 - w17 E11.5 - E16.5 Branching 
Canalicular w16 - w26 E16.5 - E17.5 Proximo-distal differentiation 
Saccular w24 - w38 E17.5 - P5 Continued differentiation 
Alveolar w38 -  P5 - P30 Alveologenesis 
         
 
Table 1. Histological stages of the human and murine lung development. Indicated are the stages, time 
spans and processes involved in lung formation and maturation. E: embryonic day; P: post-natal day; W: 
week. 
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1.1.2 Airway epithelial cells 
 
A greater knowledge of the structure and function of the airways is essential to advance 
our understanding of pulmonary disorders. Pathological airway remodeling, including 
impaired epithelial differentiation, goblet and basal cell hyperplasia, goblet and 
squamous cell metaplasia/dysplasia and epithelial to mesenchymal transition are 
integral parts of many lung diseases [21, 22]. In addition, alterations that do not directly 
involve the epithelium, including smooth muscle hyperplasia, thickening of the basal 
lamina as well as fibrosis and inflammatory cell accumulation also occur in lung 
diseases. Although the fundamental roles of these changes have been documented, the 
etiology of airway remodeling remains poorly understood [21]. 
 
The respiratory epithelium consists of at least eight distinctly different epithelial cell 
types with unique morphology (Figure 2) [10] . Based on ultrastructure, function and 
biochemistry, these cells can be grouped as basal, ciliated, secretory or neuroendocrine 
cells. Airway epithelial cells are polarized, with an apical side facing the airway lumen, 
and a basal side resting on the basement membrane and lamina propria. The latter rests 
upon the submucosa and contains bronchial blood vessels, nerve bundles, mononuclear 
cells as well as fibroblasts. The submucosa of the trachea and large bronchi includes a 
large amount of mucus producing glands, muscle cells and cartilage, and lies on a thin 
adventitial coat. The epithelial cells of the airways form a semi-impermeable sheet, 
held together by anchoring junction proteins, i.e. tight junctions, intermediate junctions 
and desmosomes. These proteins contribute to homeostasis by selectively regulating the 
passage of water, ions, small neutral molecules and inflammatory cells. Tight junctions 
are the most apical junction proteins and consist of intricate belt-like networks of 
strands and grooves across neighboring airway cells, and are reportedly altered in 
inflammatory lung diseases [23]. In addition, integrins mediate contact to inflammatory 
cells and adhesion to components within the extracellular matrix, and thereby 
contribute to the stability of the airway epithelium as well as immune responses [24]. 
 
 
 
 
 
Figure 2. Airway epithelial cells. Ciliated cells, the most abundant cells in the human airways (depicted 
on the far left) express β-tubulin and FoxJ1. Mucus cells (seen third from the left) express mucins such as 
MUC5AC and MUC5B, and the glycogen in these cells stain positive with periodic-acid Schiff staining. A 
Clara cell, the most abundant cell type in the murine airway, is illustrated with the characteristic 
granules, (seen as the unciliated cell in the middle). Clara cells are defined by the expression of the Clara 
cell secretory protein (SCGB1A1). Basal cells (far right) express keratin (KRT)5 and KRT14. 
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The epithelium of the larynx is composed of stratified squamous cells, but in the 
trachea and main bronchi this is replaced by a pseudostratified columnar epithelium, 
which is predominated by ciliated and basal cells and interspersed with mucus cells. In 
the more distal conducting airways, there is a simplified columnar epithelium 
consisting of ciliated, basal, and Clara cells. Finally, in the most distal parts of the 
airways, the respiratory bronchioles, a simple cuboidal cell layer is found, consisting 
entirely of ciliated and Clara cells. In the distal parts of the lung, Clara cells replace 
mucus cells, which are rarely found in the distal airways [25, 26]. The mechanisms that 
control differentiation of the different cell types constituting the airway epithelium are 
highly complex and generally involve cell-cell, as well as autocrine-paracrine 
interactions, with activation of key transcription factors [1, 10, 27-30]. There is still an 
incomplete understanding of these mechanisms, although the processes are under 
intense scrutiny.  
 
Basal cells  
Basal cells, which have been proposed to be the primary stem cell in the human airway, 
give rise to both ciliated and secretory cells [2, 31, 32]. Basal cells constitute 6-30% of 
the epithelial cells in the airways [21] but are sparse in the distal airways, where Clara 
cells are suggested to act as the primary stem cells [2]. The transcription factor TRP-63 
(p63) is together with members of the FOX and sex determining region box (SOX) 
family, as well as cytokeratin (KRT)5 and KRT14 expressed in basal cells [33, 34]. 
Evidence also suggests that Notch signaling is essential for the differentiation of this 
epithelial lineage [35]. Furthermore, C/EBPγ is upregulated in basal cells compared to 
differentiated epithelial cells [34], indicating a role for this C/EBP family member in 
processes associated with lung epithelial differentiation.  
 
Ciliated cells 
The predominant cell type in the human airway, the columnar ciliated epithelial cell, is 
critical for the unidirectional transport of mucus from the lung and thus plays an 
important role in host defenses by removing inhaled particles and microorganisms [2]. 
It is fairly well-established that ciliated, basal and secretory cells are derived from a 
common progenitor that expresses SOX-2 and that basal cells can differentiate into 
both ciliated and secretory cells. The SOX-2 transcription factor, which is negatively 
regulated by Wnt signaling, is proposed to be central in airway epithelial differentiation 
[1, 36-38]. In addition, expression of the transcription factor FoxJ1 is necessary for 
ciliated cell commitment from undifferentiated cells. FoxJ1 is detected specifically in 
ciliated cells and is used as a marker for this cell lineage [39, 40].  
 
Secretory cells 
In the airways, the correct amount of mucus, with the optimal composition and 
viscoelasticity is, together with cilia activity, central for efficient mucociliary clearance 
and thus innate immune defenses. Mucus hypersecretion is an intricate part of 
inflammatory lung diseases, and a hallmark of chronic obstructive pulmonary disease 
(COPD). Two different cell types secrete mucus; goblet cells and the mucus cells of the 
submucosal glands, which morphologically resemble goblet cells. The result is a 
complex mixture of mucus proteins. One of the main constituents of mucus, mucins 
(i.e. MUC5AC and MUC5B), are large glycoproteins that serve as markers for goblet 
cells [2]. Although dysfunctional mucus production in diseases like COPD is 
incompletely understood, studies have suggested important roles of, for instance, the 
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SAM pointed domain containing ETS transcription factor (SPDEF) [41], as well as 
Notch signaling in mucus cell hyper- and/or metaplasia [42, 43].  
 
Another secretory cell type, Clara cells (Figure 3), contain electron-dense granules and 
are found in the bronchial and bronchiolar airways. In humans, their abundance is 
relatively low compared to the airways of mice, in which this is the most abundant cell 
type. Clara cells express high levels of secretoglobin (SCGB)1A1 (also known as 
uteroglobin or Clara cell (secretory) protein [CCSP/CC10/CC16]), a 10-16 kDa 
secreted protein with suggested immune modulatory properties [44, 45]. The secretion 
of host defense molecules such as surfactant proteins (SP) A and D and SCGB1A1 
suggests that Clara cells are important for innate immune responses, and may 
participate in the regulation of inflammatory responses in the lung. The expression of 
SCGB1A1 is reduced in patients with COPD [46], acute lung injury [47, 48] and 
infants with bronchopulmonary dysplasia (BPD) [49, 50], indicating a role in 
inflammatory lung diseases. Clara cells also express high levels of cytochrome P450 
monooxygenases, which are key in metabolizing xenobiotics.  
 
 
 
 
 
Figure 3. Clara cell differentiation. Clara cells are non-mitotic cells at homeostasis. Quiescent stem 
cells (vCE) are activated by epithelial injury and gives rise to facultative progenitor Clara cells, as well 
as vCE by self-renewal. Facultative progenitors can give rise to dedifferentiated mitotic Clara cells (type 
A). These in turn differentiate into type B Clara cells, or Ciliated cells. Type B can differentiate into 
facultative progenitors, and these may differentiate into mucus cells [51].  
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Similar to basal cells, Clara cells may also to have stem cell capabilities [2]. More 
specifically, (variant) Clara cells are suggested to maintain the facultative progenitor 
pool by proliferation (Figure 3). These cells may also have the capability to alter their 
phenotype as the surrounding environment changes and to restore terminally 
differentiated cells of the small conducting airways (i.e. ciliated cells) [31, 51]. An 
important role for Clara cells has also been proposed in bronchoalveolar duct junctions, 
where pollutant-resistant Clara cells could account for the proliferative cells within 
terminal bronchioles (bronchoalveolar stem cell, BASC, depicted in Figure 4), 
generating Clara cells as well as type I and type II cells [52, 53]. This is, however, 
challenged by the observation of distinct epithelial progenitor cells in the alveoli [54]. It 
has also been suggested that at least two distinct Clara cell populations reside in the 
lung, those originating from the saccular and canalicular period of lung development, 
and those resulting from differentiation of cells in the mature, post-natal lung [51]. 
Differentiation into mature Clara cells has been proposed to be promoted by a number 
of transcription factors [55, 56], as well as Notch and Wnt signaling [57, 58], although 
contrasting evidence on the importance of Wnt/β-catenin signaling exists [59]. Thus, 
the precise processes and mechanisms that control Clara cell differentiation remain 
unsubstantiated.  
 
Alveolar cells 
The alveolus consists of two highly specialized epithelial cells, the flat and elongated 
alveolar type I pneumocyte as well as the cuboidal alveolar type II pneumocyte (Figure 
4). Alveolar type I cells facilitate gas exchange and are derived from type II cells. The 
cuboidal type II cells mediate fluid and ion transport, in similarity with type I cells and 
produce both the lipid as well as the protein components of surfactant [60]. Pulmonary 
surfactant plays a crucial role in lowering alveolar surface tension, and additionally has 
important functions in host defenses [60, 61].  
 
 
Figure 4. Structure of the distal lung. Serous, ciliated and Clara cells line the epithelium in the 
respiratory bronchioles. In the alveoli, airway epithelial cells are replaced by flat type II pneumocytes 
and cuboidal type II pneumocytes. The bronchioalveolar stem cell (BASC),which is reportedly SP-C and 
SCGB1A1 positive, is shown at the proposed location. 
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1.1.3 The murine respiratory tree 
 
The adult murine trachea and primary bronchi are, similar to human airways, composed 
of a pseudostratified epithelium. There are, however, several distinguishing differences 
between the murine and human respiratory tree. The mouse airway is significantly 
thinner than the human airway. Additionally, in contrast to the basal, ciliated, serous, 
and goblet cells of the human proximal airways, the mouse proximal airways are lined 
with Clara and ciliated cells, with only a few basal cells. In the distal airways, which in 
mice are devoid of respiratory bronchioles, ciliated cells are scarce and the Clara cells 
make up >80% of the cells [3, 26]. In addition, the zone of transition, separating the 
conducting airways and gas exchange area with bronchial epithelial cells mixed with 
alveoli, is considerably larger in humans than in mice. Mouse airways also lack 
cartilage in the proximal airways and almost completely lack submucosal glands, 
except in the most proximal part of the trachea [3]. The differences between the human 
and murine airways could potentially have an impact on the outcome and interpretation 
of data obtained from murine models, and are thus important to consider in translational 
research.  
 
 
1.2 INNATE IMMUNITY OF THE AIRWAYS 
 
By providing the different constituents of the mucociliary layer and a physical barrier 
formed by tightly connected epithelial cells, the airway epithelium plays a crucial role 
in lung defenses. The airway epithelium is in addition a central contributor to innate 
and adaptive immune responses by the production and secretion of molecules involved 
in host defenses as well as recruitment and interaction with inflammatory cells.  
 
 
1.2.1 Pathogen recognition receptors 
 
The immediate innate immune response includes the secretion of antimicrobial peptides 
and inflammatory mediators that attract and activate phagocytes. This response 
provides protection against pathogenic invasion and is initiated by the recognition of 
highly conserved microbial structures (i.e. pathogen-associated molecular patterns) by 
pattern-recognition receptors (PRRs), such as Toll-like receptors (TLRs) [62].  
 
 
Toll-like receptors  
TLRs are type 1 integral membrane glycoproteins located on the cell membrane or 
intracellular vesicles. Thirteen TLRs (named TLR1-13) have been documented in 
mammals. TLR1-10 are expressed in the humans, of which TLR2-6 exhibit the highest 
expression in lung epithelial cells [63]. Of the TLRs expressed in the airway 
epithelium, TLR1, 2, 4, 5, 6, and 9 recognize pathogen-associated molecular patterns of 
bacteria. The first identified pathogen recognition receptor (PRR), TLR4 is activated by 
lipopolysaccharide (LPS), a complex glycoprotein in the outer cellular membrane of 
Gram-negative bacteria such as Pseudomonas aeruginosa. TLR4 mainly signals via 
myeloid differentiation primary response gene (MyD)88, although alternative signaling 
pathways exist [64-67]. TLR4/MyD88 is, in addition to activation by LPS, also 
involved in inflammatory signaling evoked by for instance cigarette smoke [68-70], 
   9 
even though this inflammatory response may be in part be due to LPS activation as 
well.  
 
 
1.2.2 Host defense molecule production by epithelial cells 
 
In response to inflammatory stimuli, lung epithelial cells produce enzymes, 
permeabilizing peptides, opsonins, protease inhibitors, toxic small molecules, and 
pathogen neutralizing macromolecules, all involved in pathogen resistance. The 
secreted host defense molecules includes collectins (including SP-A and D), defensins, 
lysozyme, complement, and serum amyloid (SA)A, which together display broad 
microbicidal activity [62, 71]. SP-A, for instance, secreted by Clara cells and alveolar 
type II cells, binds to Gram-positive and Gram-negative bacteria, fungi and viruses and 
thereby enhances engulfment by phagocytosing cells (i.e. acting as an opsonin) [62, 
72]. In addition to the anti-microbial activities at high concentrations, low concentration 
of anti-microbial peptides have been reported to attract inflammatory cells. Some anti-
microbial molecules have been shown to increase interleukin (IL)-8 levels and even 
induce epithelial cell lysis, in a possible attempt to promote inflammation. 
Antimicrobal peptides can also induce wound repair, proliferation, or differentiation, 
dependent on cell type [62].  
 
 
1.2.3 Inflammatory mediator production by epithelial cells 
 
In addition to the production and secretion of anti-microbial molecules, airway 
epithelial cells also to secrete a number of inflammatory mediators, including 
cytokines, chemokines, and other cell signaling molecules. Cytokines are soluble 
proteins or peptides with autocrine, paracrine, or endocrine activity at low 
concentrations. Chemokines are cytokines classified according to their capacity to 
induce leukocyte infiltration. Epithelial cells produce the neutrophil chemoattractant 
IL-8 (chemokine (C-X-C motif) ligand (CXCL)8), as well as the murine counterparts 
growth related oncogene (GRO)α (CXCL1) and macrophage inflammatory protein 
(MIP)-2 (CXCL2), the pro-inflammatory IL-1β, IL-6 and tumor necrosis factor 
(TNF)α, granulocyte macrophage-colony stimulating factor (GM-CSF), granulocyte-
colony stimulating factor (G-CSF), as well as transforming growth factor (TGF)α and β 
[64]. In addition, epithelial cells express inflammatory genes such as nitric oxide 
synthases (NOS) [73] as well as cyclooxygenases (COX), lipooxygenases, and 
prostaglandin synthases, all involved in the generation of lipid mediators involved in 
inflammatory signaling [74]. Taken together, lung epithelial cells are thus pivotal 
players in the orchestration as well as the regulation of immune responses in the lung.  
 
 
1.2.4 Inflammatory cell recruitment by the airway epithelium 
 
The secretion of inflammatory mediators signals the presence of pathogens (and/or 
microbial products) and attract innate immune cells, such as neutrophils, macrophages, 
dendritic cells and natural killer (NK) cells, as well as cells within the adaptive immune 
response. As epithelial cells express cytokine receptors on the cell surface, epithelial-
derived cytokines also serve to amplify inflammatory responses. Airway epithelial cells 
moreover regulate adaptive immune responses through direct interactions with different 
cell surface receptors on dendritic cells, T helper (Th)1 and Th2 cells, as well as B cells 
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[71]. In the work included in this thesis, the focus has been on the role of the lung 
epithelium in innate immune responses, with particular emphasis on neutrophils.  
 
Neutrophils 
The polymorphonuclear neutrophil is a short-lived phagocyte that is produced in the 
bone marrow and mobilized to the circulation upon inflammatory stimulation. In 
healthy individuals, neutrophils do not account for more than about 1% of the 
inflammatory cells in the lungs [75], but are rapidly recruited to sites of inflammation 
in high numbers. Neutrophils are attracted to inflammatory foci by the chemokines IL-
8, GROα, MIP-2, ENA-78 (CXCL5), and lungkine (CXCL15). This recruitment, in 
which lung epithelial cells play key roles, involves the upregulation of cell adhesion 
molecules as well as rolling, tethering and passage through capillary walls (i.e. 
diapedesis) [67]. Neutrophils possess the capability of sensing pathogen-associated 
molecular patterns and respond by activating and fine-tuning effector functions [76]. 
Upon phagocytosis, internalized microorganisms are eliminated by the release of 
reactive oxidative species and proteases into the neutrophil endosome. Furthermore, 
and in similarity with epithelial cells, neutrophils secrete anti-microbial peptides such 
as defensins, in addition to proteases and reactive oxidative species. The importance of 
neutrophil recruitment is emphasized by studies in transgenic mice with enhanced 
expression of the neutrophil chemoattractant GROα. When infected with Klebsiella 
pneumonia, these transgenic mice display increased neutrophil recruitment and 
bacterial clearance as well as improved survival [77]. However, molecules secreted by 
activated neutrophils can cause substantial damage, in particular in chronic 
inflammatory conditions [67, 78]. In acute respiratory distress syndrome (ARDS), a 
severe systemic or local microbial infection leads to a large neutrophil recruitment to 
the lung. The steroid responsiveness of the disease is poor and the mortality is high, in 
between 40-60% [79]. 
 
Mononuclear cells 
In similarity with neutrophils, mononuclear phagocytes (i.e. monocytes and 
macrophages) are bone-marrow derived myeloid leukocytes. Macrophages, which 
account for approximately 95% of the inflammatory cells in the healthy lung, serve as a 
first line of defense and are critical for both innate and adaptive immune responses in 
the lung. Mononuclear phagocytes are recruited to the lung by IL-1β, MIP-1α (CCL3), 
monocyte chemoattractant protein (MCP)1/CCL2, and TNFα [73, 80]. Alveolar 
macrophages, located at the interference between lung tissue and air are pivotal in 
pathogen internalization and phagocytosis [73, 80]. The dysregulated function of these 
cells, however, putatively contributes to the alveolar destruction and emphysema 
characteristic of COPD [81].  
 
In summary, lung epithelial cells are essential in pulmonary innate immune responses 
as well as immune regulation, and control host defenses in close interaction with 
polymorphonuclear and mononuclear cells. Although the mechanisms controlling the 
functions of the airway epithelium have been investigated, there are still insufficient 
data on the regulation and control of airway epithelial cell functions. Growing evidence 
suggests that members of the C/EBP family of transcription factors play vital roles in 
controlling differentiation and innate immune defenses in various organs, and possibly 
also in the airway epithelium. 
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1.3 CCAAT/ENHANCER BINDING PROTEINS 
 
C/EBPs belong to the basic region-leucine zipper (bZIP) family of transcription factors 
and are ubiquitously expressed [82, 83]. C/EBPα, the founding member of the family, 
was identified by McKnight and colleagues as a protein in rat liver nuclei capable of 
binding the CCAAT box motif present in various gene promoters [84]. C/EBPβ was 
later recognized as a factor binding to an IL-1 responsive element in the IL6 gene [85]. 
During the following decade, four additional members were identified in mammalian 
species and subsequently named in succeeding order according to the Greek alphabet 
(C/EBPα, β, γ, δ, ε, ζ) [82, 83] (Table 2). 
 
1.3.1 C/EBP structure and function 
 
All C/EBPs are composed of separate, highly conserved domains (Figure 5). Some 
regions, however, are unique and distinguish individual C/EBP factors. For instance, 
C/EBPβ contains characteristic regions that allows for additional post-transcriptional 
modifications, and thereby further control of the activity [86]. The positively charged 
basic region binds directly to the negatively charged DNA [86]. The DNA sequences 
that all lung-enriched C/EBPs (C/EBPα, β, and δ) interact with are virtually identical, 
although some differences in binding site specificities have been reported, in particular 
for C/EBPβ [87-91]. Thus, functional replacement with regard to activating gene 
transcription by different C/EBPs is conceivable. The basic-leucine zipper (bZIP) 
domain is the most C-terminal region and is crucial for homo- and heterodimerization 
(Figure 6), which in turn is required for DNA binding [91]. All C/EBPs can form 
heterodimers in all intrafamiliar combinations. Dimerization is of particular interest for 
inflammatory and anti-inflammatory signaling, since different combinations may result 
in pro- or anti-inflammatory responses (reviewed in [92]). In addition, the bZIP region 
also serves as a nuclear localization signal and extensions of the bZIP region mediate 
various protein-protein interactions with other cellular proteins [86]. The 
transactivation domain, harbored in the amino-terminal portion of the protein, is not as 
conserved as the leucine zipper or basic domains. The transactivation domain interacts 
with different components of the basal transcription apparatus and thereby stimulates 
transcription. C/EBPγ, however, lacks the transactivation domain and therefore acts to 
repress gene transcription, even though the function may diverge in different cell types 
[86]. In addition to the domains mentioned above, C/EBPβ contains negative regulatory 
regions in the N-terminus, although the precise role of these regions remains unknown 
[91].  
 
Table 2 
Nomenclature of the C/EBP family 
Name Alternate name 
C/EBPα p42, p30 
C/EBPβ NF-IL6, LAP, LAP1, LAP*, LAP2, LIP, CRP2, IL-6DRP, NF-M, C/EBPβ-1, C/EBPβ-2 
C/EBPγ Ig/EBP, GPE1BP 
C/EBPδ NF-IL6β, CRP3, CLEF 
C/EBPε CRP1 
C/EBPζ CHOP, CHOP10, GADD153, DDIT3  
     
 
Table 2. Nomenclature of the CCAAT/enhancer-binding protein and isoforms.  
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Phosphorylation and dephosphorylation of C/EBP family members commonly cause 
conformational changes or modulate the ability to interact with other transcription 
factors or co-factors, leading to effects on the transactivation capacity. Phosphorylation 
of human C/EBPβ at Thr235 (homologous to mouse Thr188) has been shown to be 
pivotal for transactivation and the induction of immediate-early inflammatory genes in 
response to inflammatory stimuli. In similarity, phosphorylation of Ser276 
(homologous to human Ser325) of the murine C/EBPβ has been attributed with a 
comparable function. There are numerous reports that collectively describe a complex 
system where phosphorylation at different sites, possibly simultaneous, directs C/EBPβ 
and determines the gene expression profile of a cell [86]. In addition, inhibitory 
SUMOylation and stimulatory or inhibitory acetylation of C/EBPβ have been described 
[86], endowing the system with additional complexity.  
 
 
1.3.2 Lung-enriched C/EBPs 
 
Of the C/EBP-factors, C/EBPα, β, and δ are lung-enriched and the ubiquitously 
expressed C/EBPγ and ζ are also expressed in the lung [93]. Among these, C/EBPβ has 
been reported to be the dominant DNA binding factor in the adult human airway 
epithelium [94]. The number of C/EBP isoforms, however, widely exceeds the C/EBP 
genes expressed in a specific cell type. While C/EBPζ contains four introns, C/EBPα, β, 
δ, and γ are intronless. Due to leaky ribosomal scanning, the same intronless mRNA 
molecule can be translated into different polypeptides by alternative use of translation 
initiation codons. Thus, two polypeptides, 42 kDa and 30 kDa, with different activation 
potential, can be produced from the C/EBPα mRNA sequence [95]. In similarity, three 
C/EBPβ isoforms have been identified, the 38 kDa liver-enriched transcriptional 
activator protein (LAP*/LAP1), the 35 kDa LAP/LAP2 and the 20 kDa liver-enriched 
transcriptional inhibitory protein (LIP). The LIP protein lacks a transactivation domain 
and represses gene expression, suggestively by inhibiting the function of other C/EBP 
isoforms in a dominant negative fashion [91, 96]. This is further complicated by the 
preference of the negative regulatory C/EBPζ to bind LIP [86]. Collectively, various 
combinations of isoforms with different transactivation potential could have a profound 
effect on the regulation of target genes.  
 
 
 
 
 
Figure 5. Schematic illustration of the CCAAT/enhancer-binding proteins (C/EBPs). The different 
domains and their primary functions are indicated. Adapted from [93]. 
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Figure 6. Protein structure of CCAAT/Enhancer-binding proteins. Two C/EBPβ monomers dimerize 
and bind to DNA. Adapted from [91]. 
  
 
Role of C/EBPα in differentiation and proliferation 
The founding C/EBP family member, C/EBPα, plays a pivotal role in inhibiting 
proliferation in several organs, including the lung [97-99]. For example, a notable role 
for C/EBPα as a master inhibitor of proliferation, and in promoting the differentiation 
of progenitor cells into the myeloid linage has been documented. C/EBPα is highly 
expressed in granulocyte and monocyte progenitor cells and mutations in the gene or 
DNA methylation of the promoter are frequently detected in acute myeloid leukemia 
[100]. In addition, glucocorticoid (GC)-induced differentiation of preadipocytes is 
mediated via C/EBPα dependent transcription of C/EBPβ, which interacts with histone 
deacetylase (HDAC)1 and facilitates transcription of genes associated with 
differentiated cells [101]. GC induction of hepatocyte differentiation has similarly been 
reported to be dependent on C/EBPβ [102].  
 
Deletion and ectopic expression of C/EBPα has revealed a vital role in regulating 
proliferation in the alveolar epithelium [15, 18, 19, 98, 103]. Deletion of C/EBPα 
during lung development causes impaired lung maturation and hyperproliferation of 
alveolar type II cells [18, 19, 91, 98, 104]. It has previously been reported that C/EBPα 
mediates growth arrest by interacting with cyclin-dependent kinase (cdk) 2 and 4, two 
critical regulators of cell cycle progression [105]. C/EBPα also represses the activation 
of E2F, which is necessary for passage through the cell cycle restriction point [106, 
107]. In addition, C/EBPα is required for GC-induced transcription of the cdk inhibitor 
p21WAF/Cip1 [108, 109], an anti-proliferative factor exhibiting increased expression in the 
bronchial epithelium of asthmatics as well as COPD patients [110, 111]. Also, the anti-
proliferative effect of GCs in lung mesenchymal cells has been reported to be mediated 
via the formation of a C/EBPα-GR complex [112]. Thus, C/EBPα mediates the anti-
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proliferative effects of GCs by at least two different mechanisms, suggesting that 
C/EBPα is central for the anti-proliferative effects of GC therapy in asthma. 
 
The role of C/EBPβ in proliferation 
In sharp contrast to the anti-proliferative role of C/EBPα, C/EBPβ has previously been 
suggested to support proliferation in hepatocytes after partial hepatectomy. The initial 
conclusions were, however, based on the observed decrease in C/EPBα expression and 
simultaneous upregulation of C/EBPβ after hepatectomy [113]. Further studies have 
revealed a more complex system, where the C/EBPβ isoform LAP decreases cyclin A, 
cyclin E as well as E2F and delays transition into S-phase, while the LIP isoform 
induces cyclin A and E, as well as C/EBPα [114-116]. Following cigarette smoke 
extract stimulation of lung fibroblasts, cell proliferation is reduced and C/EBPα and 
C/EBPβ are upregulated, supporting anti-proliferative roles for both these transcription 
factors [117]. In other cell types, such as adipocytes, C/EBPβ has been suggested to 
promote proliferation [118]. In addition to these documented roles in controlling 
proliferation, C/EBPβ has been attributed with anti-apoptotic functions [91, 93]. There 
is no existing evidence from mouse models that supports a vital role for C/EBPβ in 
baseline lung function or lung development [119, 120]. There is, however, still 
insufficient data on the proliferative role of C/EBPβ in the pulmonary epithelium. 
 
Role of C/EBPβ in inflammatory and acute phase responses 
Current evidence suggests that C/EBPβ plays a critical role in the hepatic acute phase 
response induced by inflammatory stimuli. C/EBP binding motifs are present in the 
promoters of many class I acute phase responsive genes, such as the gene coding for α1-
acid glycoprotein and the different SAA genes. In addition, many genes associated with 
inflammation, for instance the TNFA, IL1B, IL6, IL8, IL12, CSF3, MIP1A/CCL3, and 
MIP1B/CCL4 genes, as well as genes coding for the receptors binding for instance G-
CSF and GM-CSF contain C/EBP responsive elements, and/or have been reported to be 
regulated by C/EBPβ [86, 121, 122]. Also, the mRNA expression, isoform ratio and 
activity level of C/EBPβ are all modulated by inflammatory stimuli such as 
recombinant cytokines (i.e. TNFα, IL-1 and IL-6), as well as LPS, indicating a specific 
role for C/EBPβ in the acute phase response [90]. In line with this, C/EBPβ-deficient 
mice display an increased susceptibility to Listeria monocytogenes and Candida 
albicans infection, with reported impaired cellular immunity. Following infection with 
C. albicans, humoral and innate immune responses are also affected [90]. Some 
evidence of the involvement of C/EBPs in inflammatory responses in the lung also 
exists. Both C/EBPβ and C/EBPδ are elevated in the lung following inflammatory 
stimuli [85, 90, 91, 123-125]. Also, C/EBPβ has been suggested to transactivate 
pulmonary expressed host defense proteins, such as SP-A [93, 126], which are induced 
following inflammatory stimuli [121, 127]. C/EBP transactivation is induced by 
nucleotide-binding oligomerization domain-containing protein (Nod)1 activation in 
bronchial epithelial cells, although the transactivation capacity is not immediately 
increased by LPS stimulation in vitro [128]. Notably, the outcome of the inflammatory 
response is both stimulus- and cell type-specific [90], prompting further investigations 
into lung-specific responses.  
 
 
1.3.3 C/EBPs and lung diseases  
 
C/EBPs have been implicated in several lung diseases, including non-small lung 
cancer, asthma, pulmonary and cystic fibrosis, as well as chronic bronchitis and COPD 
[94, 104, 129-131]. Smokers with chronic bronchitis or COPD exhibit reduced activity 
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of C/EBPβ in the lung epithelium compared to asymptomatic smokers [94]. This 
decreased activity could render the epithelium more sensitive to the damaging effects of 
cigarette smoke and reduce the efficiency of host defense responses, as the induction of 
inflammatory and host defense genes would be hampered. Moreover, C/EBPβ has also 
been suggested to be important for GC signaling [132, 133], a cornerstone of the 
medical treatment of inflammatory lung diseases. Collectively, these findings stress the 
need for further studies on the disease-specific role of the C/EBP transcription factors. 
  
 
1.4 INFLAMMATORY AND SMOKING-RELATED LUNG DISORDERS 
 
Considering the possible contribution of C/EBPs to the pathogenesis of COPD and 
other detrimental lung diseases [94], there is a need to further investigate the role of 
C/EBPs in lung disorders. In papers I-IV of this thesis, the role of C/EBPs in lung 
development (relevant for respiratory distress syndrome (RDS)/BPD, smoking-induced 
lung disease such as COPD and acute lung injury are investigated and/or discussed.  
 
 
1.4.1 Bronchopulmonary dysplasia (BPD) 
 
The lungs of premature children (gestational age <28 weeks) with very low birth 
weight (<1000 g) are severely immature, and respiratory distress syndrome (RDS) is 
very common in these infants [134]. BPD is the most common chronic respiratory 
disease associated with treatment of RDS among premature children [135], affecting 
20% of all infants with birth weight <1500 g [136]. BPD is a consequence of elevated 
oxygen and ventilator-induced injury on the immature and surfactant-deficient lungs of 
premature infants [137]. The most widely accepted definition of BPD is based on 
gestational age and the requirement for oxygen supplementation. The National 
Institutes of Health has defined BPD as occurring among infants <32 weeks of post-
menstrual age that require supplemental oxygen for at least 28 days after birth. If the 
need for oxygen persists after week 36, the disease is considered to be more severe 
[135]. Less aggressive mechanical ventilation along with routinely administered 
exogenous surfactants and glucocorticoids have led to a change in the disease pattern 
and the classification of new BPD, to be separated from the old definition of BPD. The 
latter is characterized by squamous epithelial metaplasia, epithelial and smooth muscle 
hyperplasia, remodeling of pulmonary arteries, fibroproliferation as well as decreased 
alveolarization. In contrast, new BPD is not as severe and is dominated by a disruption 
in distal lung growth due to interrupted gestational growth, with fewer and larger 
alveoli [138, 139]. The alveolar simplification and enlargement is a result of an 
impairment, not arrest in postnatal alveolarization [137] and is accompanied by modest 
airway remodeling and a varying degree of arterial remodeling as well as smooth 
muscle and fibroproliferation [138, 139]. The pulmonary phenotype of CebpaΔLE mice, 
described in paper I, has greater resemblance to old BPD, although similarities exist 
with new BPD as well. At present, BPD occurs in preterm infants born at 24 to 26 
weeks of gestation, in the late canalicular-early saccular stage. As the alveoli are not 
uniformly present until week 36, in the alveolar stage, the lungs of preterm newborns at 
30 to 32 weeks, during the saccular stage and even later are considered to be immature 
[4, 137], although these children are not affected with BPD.  
 
There is increasing concern that the lung injury associated with preterm deliveries (i.e. 
BPD) may lead to chronic conditions and obstructive airways later in life. Abnormal 
baseline spirometry, as well as impaired exercise capacity and significantly more 
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respiratory symptoms are noted among childhood survivors of extreme preterm birth. 
In addition, asthma is twice as common among children born prematurely, compared to 
children born at full term [140]. Some evidence also suggests that adult survivors of 
BPD suffer from respiratory symptoms such as shortness of breath and wheeze, as well 
as airway obstruction [136]. There is still, however, missing data on the consequences 
of premature birth on the aging lung.  
 
 
1.4.2 Acute lung injury  
 
Acute lung injury (ALI) and the most severe form of the disorder, ARDS are 
characterized by lung edema with protein-rich fluid. This is caused by disrupted 
epithelial barrier functions and microvascular endothelial injury, which lead to 
increased permeability of the alveolar-capillary barrier. In the later stages, a repair 
process characterized by fibrosis and remodeling of the alveolar space also occurs 
[141]. ALI is defined as a disease with acute onset, bilateral pulmonary infiltrates and a 
PaO2/FiO2 ratio < 300 mmHg or 40 kPa (partial pressure of oxygen in arterial 
blood/fraction of inspired oxygen in a gas mixture), together with the absence of 
cardiac involvement [142]. A common cause of ALI  is pneumonia or sepsis, although 
non-infectious causes, such as exposure to noxious gases, also are well documented. 
The mortality of the more severe form, ARDS, is still approximately 40%, despite 
increasingly effective intensive care routines and thus represents a significant cause of 
morbidity and mortality in society. The most striking hallmark of the disease is acute 
inflammation with neutrophil accumulation in the alveolar space. The activated 
neutrophils subsequently cause significant tissue damage by the release of cytotoxic 
and immune activating agents such as proteases, cytokines, and reactive oxygen 
species. In murine models, the most important chemokines for neutrophil recruitment 
are GROα and MIP-2, which both bind to chemokine (C-X-C motif) receptor 
(CXCR)2, a receptor with a key role in neutrophil influx to the lung. In addition, 
multiple cytokines, including TNFα, are upregulated in ALI [79].  
 
 
1.4.3 Chronic obstructive pulmonary disease 
 
The World Health Organization has estimated that 80 million people suffer from 
COPD, a disease characterized by progressive airflow limitation in response to noxious 
particles or gases. COPD is currently the sixth leading cause of death worldwide but the 
incidence is predicted to increase dramatically in the immediate future, posing a 
substantial impact on global health and contributing to increasing medical care costs 
[143]. Cigarette smoking is exclusively the most important risk factor in COPD 
pathogenesis and smoking cessation is key to preventing disease progression. While 
continued efforts to reduce smoking prevalence are central to minimizing the burden of 
COPD [143], the addictive nature of cigarette smoking along with unsuccessful 
attempts to prevent young adults from developing harmful smoking habits underlines 
the importance of a greater understanding of the mechanisms that contribute to COPD 
pathogenesis.  
 
Spirometry is required to make the clinical diagnosis of COPD. The disease is 
diagnosed when the ratio between forced expiratory volume in one second (FEV1) and 
forced vital capacity (FVC) is <0.7, or when FEV1 is <80% of predicted  [144, 145]. A 
series of pathological lesions that cause decreased lung function develop as a 
consequence of repeated injury and dysfunctional repair processes in response to 
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cigarette smoke. These lesions include chronic inflammation and structural changes to 
the proximal and peripheral airways, lung parenchyma and pulmonary vasculature 
[143, 146]. Small airway disease (obstructive bronchiolitis), inflammation and 
excessive mucus production (bronchitis), and parenchymal destruction (emphysema) 
contribute to airflow limitation to varying degrees in different individuals [143]. 
Corresponding to this, different clinical phenotypes have been described which relate to 
clinically meaningful outcomes [147]. Increased documentation of the different clinical 
phenotypes may be used to develop new therapeutic interventions and improve COPD 
management. Small airway disease and remodeling of the airways is a cardinal feature 
that is characteristic of COPD and includes airway wall thickening, inflammatory cell 
infiltrates [146, 148, 149], and pronounced mucus/goblet cell hyperplasia [150]. Extra-
pulmonary symptoms, such as heart disease, muscoskeletal depression and underweight 
may also manifest in individual patients and contribute to disease severity, decreased 
quality of life, and morbidity [143, 151]. Despite substantial efforts, it is still uncertain 
exactly how the lesions of COPD develop [148], although it is well-known that the 
symptoms develop after years of chronic cigarette smoking [143].  
 
The occurrence of COPD exacerbations, defined as an acute and sustained worsening 
of stable COPD that requires altered medication, accounts for much of the morbidity, 
mortality and health care costs associated with the disease [152, 153]. Exacerbations 
are central in driving disease progression, with each individual exacerbation causing 
further deterioration in lung function [143, 154]. Respiratory pathogens are likely to 
cause exacerbations [155], and the virulence of the pathogen could together with 
impaired host defenses theoretically explain the amplified inflammation characteristic 
of an exacerbation [156]. Altogether, this emphasizes the need for a more 
comprehensive understanding of the host response to respiratory infections. Additional 
studies that utilize novel methodological approaches are thus warranted to improve the 
current knowledge of the mechanisms that contribute to pathogen-induced 
exacerbations and the detrimental effects of these events. 
 
The risk of developing COPD among continuous smokers has been estimated to be 
25% [157], and a small proportion of all COPD patients have never smoked [143], 
together suggesting that genetic risk factors also contribute to pathogenesis. Hereditary 
α1-antitrypsin deficiency, which causes reduced inhibition of serine proteases and 
thereby promotes the development of emphysema, is a well-known genetic factor that 
influences airflow limitation [158]. Candidate gene and genome-wide association 
studies, as well as gene expression profiling, have revealed a involvement of a variety 
of other genes, many of them implicated in inflammatory processes, with possible roles 
in COPD pathogenesis [159]. Thus, it is well-established that genes with polymorphic 
expression interact with environmental factors to influence the pathology of COPD. As 
there currently no medical treatment to prevent the progression of COPD, increased 
efforts to identify genes associated with COPD pathogenesis that can be used as 
therapeutic targets are central for improved COPD management. 
 
Inflammation in COPD 
The detrimental effects of cigarette smoke are well-established. Cigarette smoke 
induces inflammatory responses, and these in turn contribute to the airflow limitation 
observed in COPD (Figure 7) [143]. Cigarette smoking is associated with innate and 
adaptive immune responses, which are amplified after onset and with the progression of 
COPD [150, 160]. The chronic inflammation characteristic of COPD is particularly 
evident in the small airways and involves the accumulation of macrophages, B cells, as 
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well as T lymphocytes [150]. In addition, the number of neutrophils are increased in 
bronchoalveolar lavage and sputum of COPD patients [75]. Activated neutrophils 
release excessive amounts of neutrophil elastase, matrix metalloproteinases, and 
oxygen free radicals, which are central in host defenses against inhaled pathogens from 
intracellular granules. Neutrophils are thus likely contributors to the deleterious 
inflammatory responses in chronic inflammatory diseases such as COPD, due to de-
granulation and the release of stored proteases [76]. Is it today generally accepted that 
cigarette smoke-induced inflammation and inflammatory cell-derived proteases cause 
the emphysematous changes in COPD [161]. As challenged mice treated with 
antibodies targeting cytokines such as TNFα display nearly complete protection against 
experimentally-induced emphysema, inflammatory genes are implicated in tissue 
destruction and the pathogenesis of emphysema [162].  
 
A wide range of inflammatory mediators, often with overlapping functions such as 
cytokines interacting in complex networks, have been reported to be involved in COPD 
[163]. Both interleukins such as IL-1β, IL-6, IL-17 [164, 165], IL-18 [166-168], IL-22 
and IL-23 [164], as well as TNFα are implicated in COPD [75]. In addition, several 
chemokines, including the neutrophil chemoattractants IL-8 and GROα are upregulated 
in COPD [149, 169], and in vitro data suggests that epithelial cells may contribute to 
these increased levels of IL-8 [170]. Nitric oxide synthases [171] and prostaglandin-
generating enzymes (e.g. COX-2) [172, 173] also play important roles disease-specific 
inflammatory signaling, and are implicated in COPD. Despite substantial efforts in 
elucidating these mechanisms, it still remains unknown exactly how the dysregulation 
of inflammatory mediators contributes to disease pathogenesis and progression. 
 
 
  
1.5 ANIMAL MODELS OF INFLAMMATORY LUNG DISEASES 
 
Animal models for several inflammatory lung diseases, including asthma [174], 
ARDS/ALI [141], BPD [137], cystic fibrosis [175], as well as granulatomous diseases 
such as sarcoidosis [176, 177] and beryllium disease [178] have been relatively well-
characterized. In contrast, there is limited documentation of animal models with a 
considerable resemblance to COPD. 
 
 
1.5.1 Models of BPD 
 
Lambs and baboons are frequently used to model BPD as both the lung inflammation 
associated with preterm birth and lung injury induced by mechanical ventilation and 
hyperoxia can be produced. Rodents have also been used to model BPD, and a 
pathology resembling both old and new BPD is produced by postnatal hyperoxia in 
mice and rats. However, an ideal model, which includes all attributes of BPD and 
allows for studies of both acute and chronic effects, as well as the outcomes of 
interventions, is yet to be produced [137].  
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Figure 7. Mechanisms of cigarette smoke induced lung pathogenesis. Adapted from [179]. 
 
 
1.5.2 Models of ALI 
 
ALI has been modeled in a wide range of animals, including rodents. There is, 
however, no animal model mimicking all the characteristics of ALI/ARDS. A variety 
of insults reproduces the acute neutrophilic alveolitis present in ALI/ARDS, including 
hyperoxia and LPS administration. LPS administration may be intravenous, 
intratracheal or intrapulmonary, which affects the outcome of the injury. Intravenous 
administration primarily causes apoptosis of endothelial cells, which precedes other 
tissue damage. There are many advantages to LPS-induced lung injury, such as 
reproducibility and accessible administration, although the epithelial and endothelial 
damage is not as severe as in clinical ALI/ARDS. In addition, LPS challenge results in 
an incomplete picture of the tissue damage caused by live bacteria in clinical settings 
[141]. 
 
 
1.5.3 Models of COPD 
 
Smoke-induced diseases such as COPD are extremely difficult to model, in part since 
the pathology involves a slow evolution and long chronicity. Animal models 
recapitulating different pathological lesions of COPD have previously been 
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documented, although there is currently no animal model that mimics all the 
pathological hallmarks of COPD, as well as the airway obstruction. Quite a large 
number of studies have produced emphysematous changes in mice and investigated 
cellular or molecular components with possible roles in the pathogenesis [180]. 
Emphysema may, for example, be produced by chronic cigarette smoke exposure, and 
the observed inflammatory responses associated with cigarette smoke exposure have 
been suggested to drive the airspace enlargement [162]. There is also evidence of 
airway remodeling following cigarette smoke exposure [180]; however, only small 
increases in secretory cells are observed [148]. Nevertheless, mice are not ideal to 
model COPD. The perfect animal model of COPD should have pulmonary anatomy 
similar to humans, since the anatomy of the lung is pivotal for the pathophysiology of 
COPD [148]. As previously discussed, the murine airways differ from the human 
airways in several aspects. Taken together, this raises the question as to whether all the 
phenotypes and hallmarks COPD [180] can be modeled in animals, or if efforts should 
instead be made to identify different suitable models reflecting the diverse phenotypes 
of COPD. For instance, a hallmark of COPD, pulmonary neutrophilia [149], can be 
induced by the LPS challenge (used in paper IV) [181]. In addition, cigarette smoke-
induced inflammation, as studied in paper III, is an integral part of COPD and the 
responses to cigarette smoke as well as role in pathogenesis of the disease are important 
aspects to gain further knowledge on.  
 
Cigarette smoke-induced inflammation 
Acute to sub-acute cigarette smoke stimulates the release of inflammatory mediators 
such as cytokines and chemokines (e.g. IL-8 and IL-1), as well as growth factors (such 
as G-CSF and TGF-β), leading to inflammatory cell recruitment and increased mucus 
production [150]. In addition, gene expression studies have revealed increased 
expression of 175 genes, including xenobiotic enzymes, anti-oxidants, and putative 
oncogenes, in the bronchial epithelium in cigarette smokers. Expression of genes 
involved in immune regulation and tumor suppressor genes were in contrast decreased 
in the bronchial epithelium of smokers [150].  
 
 
1.6 LONG-ACTING 2-AGOINST AND GLUCOCORTICOID THERAPY 
 
1.6.1 β2-adrenoceptor agonists 
 
Short acting β2-adreonceptor agonists (SABAs) are rapid and effective first choice 
bronchodilators in asthma therapy [182]. Administration of β2-adreonceptor agonists 
may moreover be beneficial in the treatment of BPD, although the subject is 
controversial, as it is debated whether the airways of preterm neonates respond to β2-
agonists [135]. Documentation of a potential benefit of β2-agonist therapy for the 
treatment of ALI in pre-clinical settings exist [183], as β2-agonists have been proposed 
to accelerate the resolution of pulmonary edema [142], as well as wound repair [184], 
although the results from a recent clinical trial was disappointing [185]. The 
development and clinical application of long acting β2-adreonceptor agonists (LABAs) 
and phosphodiesterase (PDE)4 inhibitors have led to the discovery that cAMP elevating 
agents may come with other beneficial effects, in addition to bronchodilation. For 
instance, pulmonary neutrophilia and IL-8 levels among patients with severe asthma or 
asthma exacerbations are reduced by the LABA formoterol [186].  
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β2-adrenoceptor signaling 
β2-adrenoceptor agonists exert their effects by binding to the adrenergic β2-receptor, a 
member of the seven transmembrane G protein-coupled receptor family. The activated 
receptor induces the activity of multiple variants of adenylyl cyclase (AC), enzymes 
with the capability to convert adenine triphosphate (ATP) to cyclic adenine 
monophosphate (cAMP). The second messenger cAMP interacts with protein kinase 
(PK)A, as well as different PKA variants, including phosphodiesterases, and PKA 
anchoring proteins [182]. PKA, in its turn induces smooth muscle cell relaxation 
through effects on ion channels. Bronchodilation mediated by β2-adrenoceptor agonist 
smooth muscle cell relaxation is central to the pharmacological treatment of 
inflammatory lung diseases. It is also well-established that PKA initiates a 
phosphorylation cascade, which influences gene transcription. There may also be β2-
adreonceptor signaling pathways that are independent of cAMP and PKA [187].   
 
Anti-inflammatory effects of β2-adrenoceptor agonists 
Although the most important role of β2-adrenoceptor agonists in medical therapy of 
inflammatory lung disorders are the bronchodilating properties along with potentiation 
of glucocorticoid effects, β2-adrenoceptor agonists display anti-inflammatory effects 
even when used alone [188]. A suppressive effect on inflammatory mediator expression 
has been observed in bronchial epithelial cells [189], even though only a few studies 
have addressed this. Contrasting reports also exist, documenting a stimulatory effect on 
rhinovirus-induced IL-6 expression in bronchial epithelial cells [190]. These in vitro 
studies are complemented by findings of reduced LPS-induced pulmonary neutrophilia 
as well as TNFα, IL-6, and MIP-2 expression by adrenoceptor stimulation in vivo [191-
193]. 
 
 
1.6.2 Glucocorticoids 
 
The inflammation of many respiratory disorders is effectively suppressed by 
glucocorticoids (GCs). For instance, preterm neonates with RDS/BPD are routinely 
treated with exogenous steroids [135]. The clinical benefit of GC treatment in 
ALI/ARDS is limited [142], although the outcome of reported studies are not in 
agreement. The inflammation in COPD is relatively resistant to the anti-inflammatory 
effects of GCs [194]. Similarly, the inflammation in asthma is in a minority of cases 
also less responsive to steroids [195].  Several possible mechanisms of steroid 
resistance have been postulated including GR modification, increased pro-
inflammatory transcription factor expression and defective histone acetylation (for a 
recent review see [195]). A lack of efficient medical therapy poses a major obstacle in 
COPD management, and increasing effort is being paid to investigate the relative GC 
resistance in COPD inflammation. In paper IV, the role of C/EBPβ in mediating the 
effects of GCs and LABAs was therefore investigated. 
GCs are steroid hormones that freely diffuse through the cellular membrane and bind to 
the glucocorticoid receptor (GR) located in the cytoplasm. The GR is kept inactive by a 
multi-protein complex and is present in almost all cell types, including bronchial 
epithelial cells [196-198]. Upon binding of GCs, a conformational change that releases 
the receptor from the chaperone complex occurs, with subsequent translocation to the 
nucleus [199, 200].  
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Gene regulation by the glucocorticoid receptor 
GCs play important roles in various cellular functions such as differentiation, 
proliferation, and apoptosis. In addition, GCs regulate many different inflammatory and 
host defense genes in the lung through a number of mechanisms [108, 109, 201-205]. 
For instance, through transactivation, the active GR stimulates the transcription of anti-
inflammatory genes by binding to GREs [196, 206]. Transactivation does not, however, 
solely explain all the anti-inflammatory effects of GCs. The GR also binds to negative 
glucocorticoid response elements (nGRE) and decreases the transcription of cytokines, 
chemokines, and inflammatory mediators, such as COX-2 (i.e. transrepression) [207]. 
The GR also interacts with other transcription factors, such as nuclear factor (NF)κB, 
activator protein (AP)-1, and C/EBPs, and can thereby mask domains required for 
activation, dimerization, nuclear translocation signals, or DNA binding sites. Through 
these mechanisms, the activity of pro-inflammatory transcription factors is inhibited 
[208]. In addition, GR also has the ability to form dimers with other transcription 
factors when acting by transactivation or transrepression, and may compete for other 
transcription factor activating signals or inhibit interactions with the transcriptional 
machinery as reviewed elsewhere [206]. GC signaling also induces histone 
modifications as well as chromatin remodeling, and thereby decreases the transcription 
of inflammatory genes (for a review on histone modifications in lung diseases, see 
[209]). Finally, sparing or even an induction of host defense molecules by GCs have 
been reported [210] (for a review, see [211]).  
 
 
1.6.3 Long-acting β2-agonists and glucocorticoids in COPD therapy 
 
Both short-acting and long-acting β2-agonists, as well as glucocorticoids, are 
cornerstones in COPD management, although there is limited efficiency of these drugs, 
either when used alone or in combination. The lack of a truly effective medical therapy 
for COPD thus represents a challenge for the scientific community as well as the 
pharmaceutical industry.  
 
Long-acting β2-agonists in COPD management 
SABAs are the first choice of medication in COPD patients experiencing an 
exacerbation, as recommended by the GOLD guidelines [155]. In addition, long-acting 
anticholinergics (tiotropium) alone [212] or in combination with a LABA (salmeterol) 
reduce the number and severity of exacerbations, while salmeterol has no significant 
effect alone [213]. An up-to-date multi-center trial reported increased time to first 
exacerbation in COPD patients on daily tiotropium treatment as compared to salmeterol 
[214], suggesting that long-acting anticholinergics rather than β2-adreonceptor agonists 
are the preferred choice of bronchodilators in COPD therapy. Previous evidence, 
however, indicates that there are some beneficial effects with β2-adreonceptor agonists 
as maintenance monotherapy for COPD [215]. 
 
Inhaled glucocorticoids in COPD management 
Inhaled glucocorticosteroids (ICS) are routinely used in COPD management, while 
systemic corticosteroids are recommended in severe COPD (baseline FEV1 <50% of 
predicted) [155].  There is, however, no consensus on whether ICS influence the 
natural course of COPD, or attenuate the long-term decline in lung function [143]. 
Two recent studies evaluating large cohorts have challenged previous conceptions 
and concluded that an ICS (fluticasone) with or without a LABA (salmeterol) 
significantly reduces the deterioration in lung function [216, 217]. ICS also improve 
health status by reducing the frequency of COPD exacerbations [218], lower all-cause 
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mortality [219], and slow down the decline in quality of life [220]. Thus, there are 
some beneficial effects of ICS in patients with COPD, although the inflammation of 
COPD is relatively steroid unresponsive.  
 
Combination therapy with inhaled corticosteroids and long-acting β2-agonists 
Compelling evidence from the clinic suggests that there are beneficial effects of 
combining ICS with LABAs. The dose of the ICS can be maintained at a lower level, 
since ICS with a LABA demonstrate improved effectiveness compared to ICS alone. 
It has furthermore been demonstrated that the rate of asthma exacerbations and 
hospital admissions are reduced with combination treatment [221]. In addition, as 
mentioned earlier, reduced decline in lung function is observed in COPD patients on 
ICS treatment with or without an added LABA [216, 217]. Moreover, the frequency 
and severity of COPD exacerbations are decreased by maintenance treatment with 
combination therapy of GCs and LABAs [222, 223]. Synergistic inhibition of 
inflammatory mediator expression in lung cells in vitro has also been reported [224], 
providing a possible mechanistic explanation to how the synergy of ICSs and 
LABAs. In addition, recent evidence suggests that glucocorticoid insensitivity is 
reversed by FM in peripheral blood monocytes obtained from COPD patients and that 
this may be mechanistically explained by an inhibition of phosphoinositide 3 kinase δ 
[225], which plays a central role in inflammatory responses [226]. 
 
 
1.6.4 C/EBPβ as a mediator of glucocorticoid and β2-adrenoceptor 
signaling 
 
Evidence suggests that GCs regulate the transcription of some genes through C/EBPs 
[112, 132, 133, 210], and that the GR interacts with, or signals to C/EBPβ via an 
unknown intermediate factor [133, 227]. In the lung, GCs contribute to the maturation 
of the developing lung and antenatal GC administration increases lung maturation and 
surfactant production [228]. In line with this, GR-deficient mice display lung 
immaturity with increased proliferation as well as reduced expression of pulmonary 
surfactant, and die shortly after birth due to respiratory failure [204, 205]. In spite of 
this, functional binding sites for the GR has not been found in the promoter of any 
genes coding for surfactant proteins [229]. Moreover, mice with a mutation in the GR 
causing an inability to bind to DNA are viable and exhibit normal lungs, demonstrating 
that impaired lung maturation caused by the ablation of GR is not dependent on DNA 
binding [230]. This suggests that protein-protein interactions between the GR and other 
transcription factors are more important during lung development than GR 
transactivation. The absence of functional binding sites for the GR in the promoters of 
lung-specific genes associated with the differentiated lung epithelium, such as the 
surfactant proteins and CCSP/SCGB1A1, also support the notion that the GR does not 
transactivate these genes directly but rather interacts with other proteins with 
transactivation capability, which mediate the effects of the GR. Since the activity of 
C/EBPβ is suppressed in the airway epithelium of COPD patients [94], it is tempting to 
speculate that the suppressed C/EBPβ activity may contribute to the reduced GC 
responsiveness in COPD. Furthermore, C/EBPβ is a known downstream target of β2-
adrenoceptor signaling in several cell types [231, 232], suggesting that C/EBPs could 
also be involved in the effects of LABAs in the lung epithelium.  
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2 SCOPE OF THE CURRENT INVESTIGATIONS  
 
 
The overall aim of this thesis was to investigate the functional roles of the lung-
enriched transcription factors C/EBPα and C/EBPβ. To this end, cell culture 
experiments were performed, and the pulmonary phenotype of mice lacking C/EBPα 
and/or C/EBPβ specifically in the lung epithelium was assessed. The pulmonary 
phenotype of mice lacking C/EBPβ specifically in the lung epithelium was studied with 
regard to response to both immunological stimuli and pharmaceutical agents used in the 
therapy of inflammatory lung disease, to assess in detail the consequences of the 
reduced activity of C/EBPβ in the airway epithelium of smokers with COPD. Since 
C/EBP transcription factors bind to virtually identical DNA sequences and functional 
replacement therefore possible, overlapping roles of C/EBPα and C/EBPβ were also 
investigated. The following three separate aims have been explored: 
 
To investigate the unique and overlapping roles of lung epithelial C/EBPα and C/EBPβ 
in pulmonary organogenesis with regard to cellular differentiation, as well as the 
consequences of C/EBPα deletion on adult lung morphology and pathology. 
 
To investigate the role of lung epithelial C/EBPβ in the inflammatory response to acute 
cigarette smoke exposure and LPS challenge, as both of these inflammatory stimuli are 
associated with COPD.  
 
To assess C/EBPβ in the lung epithelium as a possible mediator of the effects of 
LABAs and/or GCs, the mainstay medical therapy of inflammatory lung diseases, in a 
model of pulmonary neutrophilia.  
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3 COMMENTS ON METHODOLOGY  
 
 
3.1 EPITHELIAL CELLS 
 
Normal human bronchial epithelial (NHBE) cells i.e. primary cells collected by 
bronchial brushings are the preferred cells to study epithelial cells in vitro, as these cells 
are differentiated and resembles the airway epithelium (used in paper II and paper III). 
It is however difficult to control the differentiation state in culture, and there is a limited 
proliferative capability of primary cells. Another limitation with primary cells is of 
course the cost and difficulty in recruiting healthy volunteers; if not commercially 
available cells are used. For the transfection studies described in paper II and IV, 
transformed human normal bronchial epithelial cells (BEAS-2B), immortalized with 
adenovirus [233] were used. There are many different lung epithelial cell lines 
available, including adenocarcinoma derived A549, originating from alveolar type II 
cells, and mucoepidermoid carcinoma cells (NCI-H292), as used in paper III. The latter 
are representative of bronchial epithelial cells and, in similarity to BEAS-2B cells, 
express C/EBPβ [128, 234-237]. Previous studies have demonstrated a similar 
inflammatory response to cigarette smoke extract in NCI-H292 cells and NHBE cells 
[238, 239]. Thus, NCI-H292 cells represent a suitable cell line to study the 
inflammatory response to cigarette smoke extract and the role of C/EBPβ in mediating 
in vitro induction of inflammatory mediators.  
 
 
3.2 IN VITRO TRANSFECTIONS 
 
Small interfering (si)RNA or RNA interference (RNAi) was used to inhibit the 
expression of C/EBPβ in NHBE and NCI-H292 cells. siRNA was first described by 
Fire and Mello in 1998 [240], a discovery that awarded them the Nobel prize in 2006. 
siRNA has since been used for more than a decade to knock down or suppress gene 
expression. Growing concerns that off target effects may influence the outcome of 
RNAi experiments have led to the development of commercially available pools of 
several siRNAs targeting different sequences of a gene. With pooled siRNAs (used in 
papers II and III), the concentration of each individual siRNA is lower, leading to 
mimimized off target effects.  
 
In paper II, plasmids containing the rat Cebpa and Cebpb genes controlled by the 
human cytomegalovirus (CMV) promoters (pCMV-Cebpa and pCMV-Cebpb) were 
used together with a Scgb1a1-luciferase reporter plasmid (containing a 170 bp segment 
of the Scgb1a1 promoter, Figure 8) to study transactivation of the mouse Scgb1a1 gene 
[241]. The CMV promoter exhibits a constitutive, high level expression in mammalian 
cells. A Cebp-luciferase reporter plasmid with the reporter gene under the control of a 
consensus C/EBP binding site, as described elsewhere [242] was used in study IV. 
When the expressed C/EBPs are activated, the factors bind to the consensus sequence 
and activate transcription of the luciferase gene, which is easily detected by a 
luminometer. The luciferase enzyme converts the substrate D-luciferin to oxyluciferin 
in a light emitting reaction. A great advantage of this system is the linearity between the 
emitted light and transcription as well as translation of the luciferase gene, which 
enables gene promoter studies. This methodology allows for a more accessible and 
functional detection of C/EBP transactivation than electrophoretic mobility shift assay 
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(EMSA). In contrast to the EMSA technique, the Cebp-lucferase reporter plasmid does 
not allow for determination of which C/EBP activates transcription.  
 
 
3.3 TRANSGENIC MICE 
 
As compared to other organisms, mice as a model organism offer a number of 
advantages, however, also a few drawbacks. First and foremost, the mouse genome has 
been fully sequenced [243], and the murine and human genome corresponds well 
eachother, although some discrepancies exist, including differences in the immune 
system. Importantly, the pulmonary expression of C/EBPs is identical between mice 
and humans [93]. Lung development is furthermore relatively similar between the two 
species.  
 
C/EBPα knockout mice die shortly after birth due to hypoglycemia due to defetcts in 
liver metabolism. Mice lacking C/EBPβ display a complex phenotype with affected 
glucose homeostasis and compromised immune system, and half of the mice die within 
24 hours of birth. Together, this emphasizes the need for conditional knockout strains 
to study the role of these transcription factors in lung development, as well as in the 
adult lung [91]. Thus, in order to investigate the role of C/EBPs in lung development, 
pathology, inflammatory response and pharmaceutical therapy, mice with lung 
epithelial-specific deletion of C/EBPα and C/EBPβ were generated using the Cre-loxP 
system, with Cre expressed under control of the 3.7 kb human SFTPC (SP-C) 
promoter. The SFTPC promoter is active in all lung epithelial cells from at least E10 
[244, 245]. With the Cre-loxP system, an allele with the gene of interest is flanked by 
short base pair sequences (LoxP sites) (Figure 9). The so called floxed allele is next 
introduced to the genome of embryonic stem (ES) cells from mice of the 129 strain by 
homologous recombination. By using a selection marker, such as a neomycin resistance 
gene, ES clones with the floxed gene stably inserted into the genome can be selected 
for. Selected ES clones are subsequently injected into a C57/BL6 mouse embryo at the 
blastocyst stage. Offspring are mated with C57/BL6 mice to select for mice in which 
the ES cells have contributed to the germline, to generate mice that carry the 
recombinant floxed allele. The Cre recombinase is expressed under control of a cell-
specific promoter (SFTPC) in mice with an outbread ICR background. The 
recombinase will excise the floxed element in the cells to be targeted, and their 
progeny, in which the Cre-recominase has been expressed. These knockout strains 
allow for studies of the role of C/EBP transcription factors in the epithelium 
specifically, throughout lung development, as well as in different experimental settings 
in adult mice. Other lung specific promoters, such as the Scgb1a1 promoter are also 
frequently used. The first observed activity of the Scgb1a1 promoter is, however, 
observed at a later point in development (i.e. E14), in close temporal proximity to the 
first detected expression of C/EBPs in the lung, which is at E15.5 [15]. Other promoters 
with high activity early in lung development and activity in relatively few other organs, 
such as the Nkx2-1 promoter may also utilized in studies with conditional deletion of 
genes, although the activity in other organs is problematic when investigating gene 
products that are ubiquitously expressed, such as C/EBPs. 
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Figure 8. Schematic representation of the proximal Clara cell secretory protein (Scgb1a1) promoter. 
The illustration indicates the location of the C/EBP and NKX2-1 binding within the promoter, which was 
used in paper II. Numbers indicate distance from origin of transcription. Adapted from [93].  
 
 
Mice with a genetically mixed background, with a combination of the inbread 129 and 
C57BL/6 and the outbred ICR mouse strains were used in the studies included in this 
thesis, since generation of transgenic and knockout mice involves several mouse 
strains. This can be avoided by repeated back crossing to one strain, producing isogenic 
mice. This is nevertheless a time consuming and expensive procedure that may 
represent a problem, since different mouse strains are more or less sensitive to different 
challenges, and the choice of background strain would influence possible future 
investigations. In addition, investigating outbread mice, which in similarity with 
humans display a variable genetic background, includes the contribution of other genes 
on the effects of a specific gene deletion. A mixed genetic background, however, 
influences the variance and normal distribution within groups, and additionally requires 
that all the control groups have relevant genetic background. Accordingly, all wild-type 
controls used in papers I-IV were littermate controls, lacking the SFTPC-Cre allele. As 
normal distribution was not assumed among the samples, due to the mixed genetic 
background and relatively small group sizes, non-parametric statistical analysis were 
performed. The risk of small sample groups with mixed genetic background is that 
differences between groups may be undetected, due to lack of statistical power. An 
absence of a significant difference does not necessarily indicate that there is not a 
difference between the groups, simply that none could be detected. This is particularly 
true when the difference between groups approaches significance. Therefore, p-values 
below 0.1 are reported when appropriate.  
 
The basis of COPD diagnosis is important to consider when studies of pulmonary 
inflammation in animal models are conducted. Lung function tests are difficult to 
perform in rodents, and do not directly correlate to lung function tests in human 
subjects. In the studies included in this thesis, pulmonary inflammation as well as other 
pathologic lesions of COPD such as airway remodeling, but not lung function, is 
investigated. In light of that, it is essential to remember that even though the animal 
models used in the studies in this thesis may have similarities with the pathologic 
changes associated with COPD; these are by definition not models of COPD. 
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Figure 9. The Cre-loxP system. In one mouse strain (Cebpbfl/fl mice), the Cebpb gene is flanked by loxP 
sites (floxed, fl). In the other strain (SFTPC-Cre), the Cre enzyme is expressed under the control of the 
SFTPC promoter. In the offspring (CebpbΔLE mice), the Cre enzyme recognizes the loxP sites and excises 
the fragment in between the two sites (e.g. the Cebpb gene).  
 
 
3.4 CIGARETTE SMOKE EXPOSURE 
 
Several different procedures for cigarette smoke exposure have been described. For 
instance, both main stream and a combination of main stream and side stream smoke 
can be used and the animals can be restrained, or allowed to move around freely. Of 
course, restraint is disadvantageous, however, this allows for nose only inhalation, 
while whole body exposure will result in particles being deposited on the coat, with 
ingestion upon grooming. The passive nose inhalation by mice, which differs from the 
active oral inhalation by humans who smoke, is a particularly intricate problem with 
murine smoke models. In addition, although the time of exposure can be increased, due 
to practical limitations, mice are often exposed for longer periods, followed by more 
extensive periods of recovery, which also differs from the smoking pattern of humans. 
The smoke exposure systems can differ by a series of variables, such as the number of 
puffs/minute, the duration of the exposure, as well as the frequency of the exposures, 
differences that influence the outcome and can make individual studies difficult to 
compare. On the other hand, the smoking patterns of humans vary significantly 
between individuals, and it is therefore difficult to establish what constitutes a general 
smoking habit [246]. The cigarette smoke exposure system used in paper III, utilizing 
main and side stream smoke and a whole body exposure for 1 hour, two times a day 
(Figure 10A), has been extensively documented and generates a reproducible 
pulmonary inflammation [247, 248].  
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Cigarette smoke extract (CSE) exposure represents an accessible experimental 
procedure to stimulate cultured cells to the water soluble fraction of cigarette smoke. 
Thus, this extract excludes the non-soluble (hydrophobic) fraction of cigarette smoke. 
Several studies have, however, demonstrated that CSE has immunostimulatory 
capabilities, although conflicting documentation exists, especially for epithelial cells 
[249]. Cultured cells may also be exposed to cigarette smoke in air liquid interface. In 
this model, cells are grown on a membrane, with the basolateral side submerged in 
media and the apical side exposed to ambient air. This allows for direct exposure with 
cigarette smoke with a smoking chamber. Some differences in inflammatory responses 
have been documented between the smoking chamber and CSE model [250], 
suggesting that the outcome of in vitro cigarette smoke models should be interpreted 
with caution.  
 
 
3.5 LPS CHALLENGE 
 
LPS challenge is well documented model for ALI/ARDS [251] but also mimics a 
hallmark of COPD, pulmonary neutrophilia [181]. Intravenous injection of LPS, which 
primarily damages the endothelium, and subsequently causes destruction of the 
pulmonary epithelium, is the most commonly used administration in ALI models [79]. 
Nebulization of dissolved LPS produces an aerosol of fine particles that penetrates the 
conducting and lower airways, making this administration ideal to assess pulmonary 
inflammation. Recruited neutrophils causes significant alveolar tissue damage, which 
leads to edema characterized by a protein rich fluid in the alveolar region [79]. In the 
LPS-challenged mice described in paper IV (Figure 10B), with LPS dose and timing 
tuned to get neutrophil recruitment without much alveolar injury and edema, minimal 
or little edema was detected. In addition, the majority of neutrophils were observed 
surrounding the blood vessels and airways, not the alveoli. This suggests that, as 
intended, the level of alveolar tissue destruction observed in ALI was not produced by 
LPS challenge after 5 hours in this model.  
 
 
3.6 DRUG ADMINISTRATION 
 
Inhalation therapy is the most effective administration of both formoterol (FM) and 
budesonide (BUD) in patients with chronic inflammatory lung disorders. In paper IV, 
FM and BUD were, however, administered via intra-peritoneal injection, as effective 
inhalation therapy is difficult to achieve in mice. In addition, the largest portion of 
inhaled BUD is deposited in mouse gut [252]. Extensive hepatic metabolism of BUD 
motivated use of a relatively high dose [253, 254]. The hepatic metabolism of FM in 
mice is still unknown, however, the proportion of β2-adrenocoptors is lower in mouse 
lungs than human lungs [255, 256], suggesting that mice may be less sensitive to β2-
adrenoceptor agonists and require a relatively high dose of this drug as well. The effects 
of FM and BUD on baseline expression of inflammatory mediators were studied 3 
hours post administration, to detect the effects of both the more rapidly acting FM and 
the slower acting BUD. To study the drug suppression of LPS-induced inflammation, 
mice were pre-treated with the drugs 1 hour before LPS challenge, and sacrificed 5 
hours after this challenge, to allow for analysis of both early-induced and late-induced 
inflammatory mediators (Figure 10B). Pre-treatment with FM and BUD was performed 
to effectively address the contribution of C/EBPβ in preventing LPS-induced neutrophil 
recruitment in a setting relevant to COPD maintenance therapy with GCs and LABAs 
[222, 223].  
 30 
 
 
 
Figure 10. Experimental design of the cigarette smoke and LPS-induced lung inflammation models. 
CebpbΔLE or Cebpbfl/fl mice were exposed to (A) cigarette smoke for 4 or 11 days in paper III. In paper IV 
(B), mice were pre-treated to formoterol (FM), budesonide (BUD) or FM with BUD, challenged with 
aerosolized Pseudomonas aeruginosa lippolysacharide (LPS) and sacrificed 5 hours post-challenge. At 
the respective end-points, bronchoalveolar lavage (BAL) was performed and the number of inflammatory 
cells in BAL was assessed, together with the concentration of key inflammatory mediators. The gene 
expression of inflammatory mediators that have been proposed to be regulated by C/EBPs previously, 
was assessed in preserved lung tissue. 
 
 
 
3.7 SEMI-QUANTITATIVE REAL TIME PCR 
 
In paper III and IV, the main objective was to investigate and present gene expression 
data, as this directly reflects the effect of C/EBPβ deletion on gene regulation. Protein 
levels of for instance cytokines and chemokines are, in addition to being affected by 
transcriptional regulation, influenced regulatory mechanisms influencing mRNA 
stability, protein translation and stability [257]. This suggests that analysis of mRNA 
expression rather that protein levels may be more accurate to assess gene regulation. 
The gene expression data was validated on a protein level as far as possible, however, 
due to the limited material available, only the protein concentration of a selected 
number of gene products could be measured.  
 
Hypoxanthine phosphoribosyltransferase (Hprt)1 and the human homologue HPRT1, 
as well as glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were used to 
normalize gene expression. Both Hprt1/HPRT1 and GAPDH are widely and commonly 
used housekeeping genes. Previous documentation of their stability in cultured lung 
cells has been reported [258], although conflicting evidence of the stability in malignant 
lung tissue exist [258, 259]. The expression of Hprt1, HPRT1, or GAPDH did not differ 
between the groups with any treatment, in any of the studies. The data included in this 
thesis are presented as expression relative to the control gene (ΔCt normalization) or 
relative to the control gene and control condition (ΔΔCt normalization). In paper III and 
IV, the individual values of CebpbΔLE and Cebpbfl/fl mice of each treatment group were 
normalized to the corresponding control group, to allow for efficient evaluation of 
treatment effects.  
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3.8 STATISTICAL ANALYSIS 
 
All statistical analysis on the experimental studies performed in murine models 
presented in this thesis were performed with non-parametric tests, namely Kruskal-
Wallis one way ANOVA to test for treatment effects, and Mann-Whitney unpaired U-
test to test for individual differences between groups. The statistical analysis on 
experiments performed in cultured or freshly isolated cells were performed with 
parametric, unpaired t-tests. Alternatively, statistical analysis with multiple 
comparisons, such as described in paper IV, could be performed with Kruskal-Wallis 
tests combined with post-hoc tests, such as a Dunn’s test. While performing multiple 
unpaired t-tests increases the risk of discovering false positive differences (type I 
errors), the risk of correcting for multiple comparison by performing one way ANOVA 
together with a post-hoc test increases the chance of not detecting differences (type II 
errors) due to lack of statistical power. This is particularly true for data sets with small 
sample sizes, such as the data presented in paper IV. In light of this, unpaired t-tests 
were performed.  
 32 
4 RESULTS AND DISCUSSION 
 
 
4.1 FUNCTIONAL ROLE OF C/EBPIN THE LUNG EPITHELIUM 
 
C/EBPα plays a key role in cell differentiation and the induction of genes associated 
with the mature differentiated organ in several tissues [91]. In addition, C/EBPα 
inhibits proliferation by interacting and repressing cdk2, cdk4, and E2F [106, 107], as 
well as by inducing p21WAF/Cip1 [108, 109]. In paper I, the significance of C/EBPα lung 
epithelial deletion on lung organogenesis was investigated. Furthermore, the embryonic 
lung immaturity in mice lacking lung epithelial-C/EBPα presented an opportunity to 
assess the long term consequences of pulmonary immaturity at birth. Hence, the 
pulmonary phenotype was assessed in adult mice, with the hypothesis that 
developmental defects may induce pathological changes in the adult lung. 
 
 
4.1.1 Impaired lung development in Cebpa∆LE mice  
 
To address the outcome of C/EBPα deletion in vivo, the pulmonary phenotype of mice 
with a lung-epithelial specific deletion of C/EBPα (CebpaΔLE mice) was assessed at the 
saccular (E18.5) and alveolar (P9) stages of lung development, as well as in adult mice 
(3 months old). CebpaΔLE mice displayed prominent interstitial tissue in the alveolar 
septa along with enlarged airspaces, which appeared to be lined with cuboidal cells in 
place of slender type I pneumocytes. These changes were present throughout both the 
saccular as well as the alveolar stages of lung development (paper I and II). Additional 
assessment revealed relatively fewer Clara cells in CebpaΔLE mice, as well as the 
presence of PAS-positive cells in the conducting airways of CebpaΔLE mice at E18.5, 
suggesting that some of the Clara cells may have differentiated into a mucus cell 
lineage (presented in paper II). Preceding publications support the findings presented in 
paper I [18, 103]; however, these studies failed to assess the consequences of lung 
immaturity caused by embryonic C/EBPα deletion on the adult lung phenotype.  
 
The pulmonary phenotype of embryonic/newborn CebpaΔLE mice is consistent with the 
pathological lesions seen in preterm infants with pulmonary immaturity [138, 139]. 
Although surfactant deficiency contributes to the disease, inflammatory responses 
caused by invasive oxygen treatment also drive the pathological changes in BPD. In 
support of this, inflammatory responses during postnatal development contribute to the 
impaired alveolarization observed in both the old and new definitions of BPD [260]. 
Others have described a central role for C/EBPα in hyperoxia. Xu and colleagues used 
inducible Cre expression to conditionally delete C/EBPα in the lung epithelium after 
birth. While these mice display normal lung structure when unprovoked, the lungs of 
C/EBPα deficient mice are severely damaged by oxygen treatment, suggesting that 
C/EBPα is required for cytoprotection during hyperoxia [261] and that CebpaΔLE mice 
may exhibit amplified responses to hyperoxia. Based on this, it would be of great 
interest to incorporate oxygen treatment into the model of pulmonary immaturity in 
CebpaΔLE mice. 
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4.1.2 Lung immaturity in Cebpa∆LE mice causes histopathological 
features similar to COPD in the adult lung 
 
As the lungs of CebpaΔLE mice mature, bronchiolar metaplasia and goblet cell 
hyperplasia persisted and the airspaces continued to enlarge. Moreover, adult CebpaΔLE 
mice exhibited an increased number of proliferating cells compared to littermate 
controls, confirming that C/EBPα plays a key role in inhibiting proliferation of the 
pulmonary epithelium. In support of this, C/EBPα expression is associated with 
proliferative arrest [15] and hyperoxia-challenged mice pre-treated with a siRNA 
targeting Cebpa display increased proliferation but decreased type II pneumocyte 
differentiation two weeks post challenge [262]. In addition to increased proliferation, a 
majority of the histopathological lesions observed in COPD was detected in adult 
CebpaΔLE mice, including free non-anchored arterioles with an irregular pattern, i.e. 
emphysema, as well as centrilobular interstitial fibrosis, bronchiolar ectasia, and mucus 
plugging. Morphological analysis, presented as mean linear intercept, confirmed that 
the emphysematous changes, i.e. the enlargement and/or destruction of alveoli occurred 
over time. This may be mechanistically explained by the inflammatory cell infiltrates 
observed in the bronchioles, alveoli, and interstitial space, along with expression profile 
of inflammatory mediators and acute phase reactants, similar to what is observed in 
COPD [149, 263]. The normal lungs of mice where C/EBPα is deleted after birth, as 
reported by others [261], suggests that the lung immaturity of CebpaΔLE mice observed 
here, not the C/EBPα deficiency in itself, instigated impaired lung homeostasis later in 
life. It is thus possible that the inflammatory changes in the lungs of CebpaΔLE mice 
drive the progression of emphysema as well as the other observed lesions.  
 
Pulmonary immaturity at birth contributes to adult airway obstruction – a link between 
BPD and COPD 
While the diagnosis of COPD is exclusively based on lung function, the disease is 
strongly associated with infiltration of inflammatory cells and thickening of the small 
airway wall, together with mucus plugging and peribronchiolar fibrosis. In addition, 
destruction of the lung parenchyma causes enlarged airspaces and loss of lung elasticity 
[149, 264, 265]. Although tobacco smoke is the etiological agent in a vast majority of 
cases of COPD, far from all smokers develop airway obstruction [143]. CebpaΔLE mice 
spontaneously developed the pathological lesions associated with COPD, without 
tobacco smoke exposure. This highlights the importance of genetic factors, as well as 
early life events such as pulmonary immaturity at birth, which may increase the 
susceptibility of developing chronic lung disorders [136, 140, 266-269]. Investigations 
into the components that contribute to airway obstruction are, however, complicated by 
the lack of a definite mechanistic explanation for the processes that drive emphysema. 
Furthermore, COPD has been proposed to be not a single disease but several different 
clinical conditions with non-reversible airway obstruction as the common feature. It is 
therefore likely that preterm infants with BPD develop airway obstruction that is 
phenotypically separate from cigarette smoke-induced disease. Careful investigations 
of the clinical phenotypes, including inflammatory profiles and airway remodeling, are 
thus imperative. Additionally, with increased survival rates of prematurely born infants, 
there is a growing need to understand the processes that drive this airway obstruction 
caused by lung immaturity at birth. Such knowledge may be used to improve future 
clinical practices and treatments for preterm infants with BPD.  
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4.2 FUNCTIONAL REPLACEMENT OF C/EBPs 
 
More than 50% of CebpaΔLE mice die at birth due to respiratory distress (paper I). The 
reason as to why far from all CebpaΔLE mice survive until adulthood is unclear, 
although the virtually identical binding preferences of the C/EBPs [89] suggests that 
individual C/EBPs may be functionally replaced by other C/EBP family members 
under some circumstances. In support of this, C/EBPα, C/EBPβ, and also C/EBPδ have 
the capability of binding the promoter of the gene coding for the mouse α1-acid 
glycoprotein [86], indicating that these factors may functionally replace each other. 
Functional replacement could also explain the lack of pulmonary phenotype in mice 
lacking C/EBPβ [119], which is somewhat surprising in light of the suggested 
importance of C/EBPβ in controlling differentiation and proliferation in several other 
organs [91, 120, 270-272]. Thus, deletion of both Cebpa and Cebpb may cause a more 
severe pulmonary phenotype than deletion of either gene alone. In paper II, transgenic 
mice as well as cultured cells were used to address the hypothesis that lung epithelial 
C/EBPα and C/EBPβ have overlapping roles in lung organogenesis and lung epithelial 
cell differentiation. Furthermore, the function of these transcription factors in the lung 
epithelium was assessed, as functional replacement could mask their definite roles.  
 
 
4.2.1 C/EBP compensates for C/EBPβ and both factors activate the 
Scgb1a1 promoter  
 
The findings in paper II demonstrate that both Cebpa and Cebpb increase 
transactivation of the Scgb1a1 promoter in BEAS-2B cells. Transactivation was, 
however, not increased with transfection of both Cebpa and Cebpb together. This 
implies that C/EBPα and C/EBPβ bind the same elements within the Scgb1a1 promoter 
and may not act synergistically, as has been demonstrated for C/EBPα and NKX2-1 or 
C/EBPδ [241, 273]. Moreover, in NBEC, suppression of CEBPB led to an increase in 
both CEBPA as well as SCGB1A1 expression. Although this does not provide definite 
evidence, it is suggestive of a compensatory mechanism where CEBPA is upregulated 
following CEBPB suppression, with subsequently more efficient activation of 
SCGB1A1 transcription. 
 
 
4.2.2 Cebpa∆LE; Cebpb∆LE mice exhibit histopathology similar to 
Cebpa∆LE mice 
 
To further investigate the suggested compensatory roles of C/EBPα and C/EBPβ in the 
lung epithelium, as suggested by the in vitro findings in paper II, the functional 
replacement of individual C/EBPs was assessed in vivo. The pulmonary phenotype of 
mice lacking both C/EBPα and C/EBPβ in the lung epithelium (CebpaΔLE; CebpbΔLE 
mice) was consequently compared to single CebpaΔLE or CebpbΔLE transgenic mice, or 
to wild-type littermate controls (SFTPC-Cre- mice). CebpaΔLE; CebpbΔLE mice 
exhibited immature lungs with interstitial tissue in the alveolar septa and enlarged 
airspaces lined with cuboidal cells during the saccular period of lung organogenesis, 
similar to what was observed in CebpaΔLE mice (paper I and II). The proliferation ratio 
was comparable between all mice during saccular development, suggesting that 
C/EBPα and C/EBPβ do not influence proliferation at this stage.  
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4.2.3 Impaired airway epithelial cell differentiation in Cebpa∆LE; 
Cebpb∆LE mice 
 
Based on the in vitro data, which suggested a partially overlapping role for C/EBPα and 
C/EBPβ in regulating SCGB1A1, the expression of SCGB1A1 was assessed in 
CebpaΔLE; CebpbΔLE mice (paper II). SCGB1A1 is secreted by Clara cells and serous 
cells in the proximal conducting airways, and putatively defines the Clara cell 
population [274]. In both SFTPC-Cre- mice or CebpbΔLE mice, SCGB1A1-expressing 
Clara cells represented the majority of the cells lining the large and small airways. The 
number of Clara cells surrounding the airway lumen was reduced in CebpaΔLE mice 
(paper II), in agreement with the observation in adult CebpaΔLE mice (paper I). This 
suggests that differentiation of the Clara cell linage is affected in the saccular stage of 
lung development in these mice. In contrast, Clara cells were almost completely absent 
in CebpaΔLE; CebpbΔLE mice, suggesting even more impaired Clara cell differentiation 
in the bronchioles of CebpaΔLE; CebpbΔLE mice, compared to CebpaΔLE mice. Thus, the 
functions of C/EBPα and C/EBPβ are central to Clara cell differentiation, with possible 
implications for lung homeostasis and host defenses. Providing additional support for a 
role for C/EBPα and C/EBPβ in regulating SCGB1A1 and Clara cell differentiation, the 
mRNA expression of Scgb1a1 was reduced by 90% in CebpaΔLE ; CebpbΔLE mice 
compared to SFTPC-Cre- mice, while no significant decrease was detected in CebpaΔLE 
mice. The expression of both C/EBPδ and NKX2-1 was, in contrast, preserved in all 
mice. Hence, in contrast to the previous suggestion [241], these transcription factors do 
not appear to be vital for SCGB1A1 regulation in the absence of C/EBPα and C/EBPβ 
in vivo. Based on these findings, it is tempting to speculate that activation of the 
Scgb1a1 promoter involves NKX2-1 together with either C/EBPα or C/EBPβ, but that 
the latter are interchangeable. It is thus likely that C/EBPs may compensate for one 
another and have partially overlapping functions regarding differentiation of the airway 
epithelium. The results presented herein suggest that either C/EBPα or C/EBPβ is 
required for Clara cell commitment. In support of this, functional redundancy of 
C/EBPs has been documented in other tissues [275, 276]. A clue to how differences in 
gene regulation may occur between different C/EBPs, even though they bind to 
virtually the same DNA sequences, is provided by the observation that C/EBPα 
together with NKX2-1 synergistically activates Scgb1a1 by binding to adjacent 
response elements in the Scgb1a1 promoter [273]. In other words, by their ability to 
differentially interact with other transcription factors, C/EBPs can achieve specificity, 
even though they bind to the same or very similar DNA segments.  
  
 
4.2.4 Ectopic mucus producing cells in the conducting airways of 
Cebpa∆LE; Cebpb∆LE mice  
 
Clara cells play important roles in the regulation of inflammatory responses [277] and 
are in addition considered to be progenitor cells for the respiratory epithelium in mice 
[278, 279]. Evidence supports a plasticity between epithelial cell populations, and Clara 
cells possess the capability to trans-differentiate into both ciliated as well as mucus 
producing cells in the adult murine lung [32, 41, 54, 280]. Hence, a defect in Clara cell 
maturation in CebpaΔLE; CebpbΔLE mice might affect other cell populations in the 
airway epithelium, such as ciliated and mucus producing cells. In agreement with this, 
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ectopic mucus producing cells were observed in the conducting airways of both 
CebpaΔLE mice and CebpaΔLE; CebpbΔLE mice, suggesting that some Clara cell 
progenitors had committed to the mucus producing cell linage. The majority of 
SCGB1A1 negative cells were, however, most probably undifferentiated progenitor 
cells, supported by increased expression of Sox2, a marker of progenitor cells [281], in 
the lungs of CebpaΔLE; CebpbΔLE mice. Mucus hyperplasia is a key pathological lesion 
of several chronic lung diseases such as asthma, cystic fibrosis and COPD [282-284]. 
Therefore, improved knowledge of mucus producing cell commitment and plasticity is 
of great clinical interest, and key to understand pathological remodeling in lung 
diseases.  
 
The evidence presented here suggests that the outcome of Cebpb deletion may differ 
when C/EBPα or other C/EBP family members have the ability to functionally replace 
C/EBPβ. This may, however, not be the case during acute phase responses to 
inflammatory stimuli, such as cigarette smoke. 
 
 
4.3 C/EBPMEDIATES INFLAMMATORY RESPONSES IN THE LUNG 
EPITHELIUM 
 
The increased activity of C/EBPβ in the airway epithelium of asymptomatic smokers 
and decreased C/EBPβ activity in smokers with COPD or chronic bronchitis [94] 
suggests a possible role for C/EBPβ in COPD pathogenesis. While C/EBPβ has been 
attributed with a pro-inflammatory role in several tissues [86, 90], the precise role of 
C/EBPβ in the airway epithelium is unknown. In light of this, the objective of paper III 
and IV was to investigate the role of C/EBPβ in inflammatory responses in the airways, 
with the hypothesis that C/EBPβ contributes to the inflammatory responses to cigarette 
smoke and LPS.  
 
Smoking is the by far most important risk factor for early-onset COPD [285]. An 
inflammatory response similar to what is observed in COPD, namely pulmonary 
neutrophilia and increased expression of inflammatory mediators, is detected in mice 
exposed to cigarette smoke [75, 76, 163-168, 171-173]. In paper III, a translational 
approach was adopted to evaluate the role of C/EBPβ in cigarette smoke-induced 
inflammation, investigating clinical samples, transgenic mice as well as human 
epithelial cells.  
 
 
4.3.1 CEBPB is downregulated in current and former smokers 
 
As a first step, the mRNA expression of CEBPB was analyzed in human airway 
epithelial biopsies from the large airways of current and former smokers, as well as 
never-smokers [286]. The expression of CEBPB was significantly lower in the airway 
epithelium of both current and former smokers, compared to never-smokers. In 
agreement with this, CSE stimulation immediately downregulated the expression of 
CEBPB mRNA as well as the C/EBP protein isoforms LIP and LAP in NCI-H292 
cells and/or NHBE cells. Based on the decreased expression of CEBPB in former and 
current smokers as well as in cultured cells exposed to smoke, it is tempting to 
speculate that downregulation of C/EBP is associated with both the short and long-
term consequences of cigarette smoking. This has possible clinical consequences in 
smoking-associated diseases that develop over the long term, and sometimes long after 
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smoking cessation, such as COPD, and warrants further studies on the role of C/EBP 
in mediating the airway epithelial response to cigarette smoke.  
 
In support of a role for C/EBPβ in mediating the inflammatory response to cigarette 
smoke in bronchial epithelial cells, NHBE cells treated with siRNA against CEBPB 
exhibited blunted induction of several inflammatory mediators, including IL8, IL6, 
IL1B and TNFA after CSE stimulation, compared to control cells. Similarly, a blunted 
inflammatory mediator response was also observed in CSE-stimulated NCI-H292 cells 
with suppressed expression of CEBPB.  
 
 
4.3.2 Impaired inflammatory cell recruitment to the lungs of cigarette 
smoke-exposed Cebpb∆LE mice  
 
To further elucidate the functional role of lung epithelial-C/EBPβ in smoke-induced 
inflammation, Cebpb∆LE and Cebpbfl/fl mice were next exposed to cigarette smoke for 4 
or 11 days, or exposed to unfiltered smoke-free room air for the same time periods. 
Reduced neutrophil recruitment was observed in Cebpb∆LE mice after both 4 and 11 
days of smoke-exposure, compared to smoke-exposed Cebpbfl/fl mice. The induction of 
inflammatory mediators was also affected in smoke-exposed Cebpb∆LE mice. Blunted 
induction of Groa and Saa3 was observed in Cebpb∆LE mice after both 4 and 11 days of 
smoke exposure. In addition, impaired induction of Il1b, Tnfa, Mip1g and Csf3 (coding 
for G-CSF) was detected with cigarette smoke exposure for 4 days in these mice. These 
inflammatory mediators attract neutrophils, promote neutrophil degranulation and are 
associated with COPD [75, 81, 149, 169, 287]. Evidence also suggests a role for several 
of these cytokines in promoting cigarette smoke-induced inflammation as well as 
emphysema, suggestively through neutrophil infiltration, although other inflammatory 
cells such as macrophages also contribute to the pathogenesis of emphysema [288, 
289]. Taken together, these findings indicate that C/EBP is central to the 
inflammatory responses to cigarette smoke, possibly by promoting neutrophil 
recruitment by increasing the expression of inflammatory mediators with neutrophil 
chemotactic activity such as Groa. In light of this, activation of C/EBPβ among 
asymptomatic smokers likely amplifies inflammatory responses, while the functional 
outcome of the decreased activity of C/EBPβ in smokers with COPD is uncertain. It is, 
however, possible that decreased C/EBPβ signaling in the airway epithelium of 
smokers with COPD contributes to Clara cell hypoplasia and mucus cell hyperplasia, as 
indicated by the findings in paper II, although further studies are needed to clarify this. 
In addition, it is also conceivable that impaired C/EBPβ signaling compromises the host 
defense mechanisms to respiratory pathogens, which are associated with both stable 
and exacerbated COPD [290-293]. Evidence suggests that the permanent presence of 
bacteria, as seen with low-grade chronic infection in the lungs of COPD patients, could 
induce an inflammatory response directly or alter the host defenses to cigarette smoke, 
as findings from experimental models suggest [248, 294-296]. Acquisition of a new 
bacterial strain, or a virus infection, with the virulence of the new pathogen, together 
with impaired host defenses as drivers, may theoretically explain the amplified 
inflammation characteristic of an exacerbation [156]. Further assessment of C/EBPβ in 
inflammatory signaling, in particular with respect to inflammation associated with 
respiratory infections, is hence pivotal for our understanding of the consequences of the 
activity of lung epithelial C/EBPβ in smokers with COPD.  
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4.3.3 Reduced respiratory neutrophilia in LPS-challenged Cebpb∆LE 
mice 
 
In paper IV, aerosolized Ps. aeruginosa LPS was used to induce pulmonary 
neutrophilia [181], a hallmark of COPD [149] in CebpbΔLE and control Cebpbfl/fl mice. 
LPS is a structural component of the Gram-negative bacterial cell wall and is thus 
associated with respiratory infections. LPS challenge is furthermore used as a model of 
acute lung injury, a syndrome with acute inflammation and edema characterized by 
neutrophil accumulation in the alveolar space [79]. The LPS-induced neutrophilia 
described in paper IV was significantly blunted in CebpbΔLE mice, possibly explained 
by a reduced expression of Groa, a neutrophil chemoattractant and murine homologue 
of IL-8 [297, 298]. In support of the chemoattractant role of GROα, the number of 
neutrophils correlated positively with the expression of Groa. In addition, blunted 
induction of Cox2, Il6 and Il1b was also observed in CebpbΔLE mice, although the 
difference compared to Cebpbfl/fl mice failed to reach statistical significance for the two 
latter parameters (p=0.064 and p=0.11, respectively). These findings support the 
findings in paper III and demonstrate that C/EBPβ has a pro-inflammatory role in the 
lung epithelium. The relatively small difference in Il6 induction observed between 
Cebpbfl/fl and CebpbΔLE mice, in contrast to earlier suggestions of C/EBPβ regulation of 
IL6 [85], suggests that the regulatory networks controlling inflammatory genes in the 
lung epithelium may vary from those in other tissues, possibly because C/EBPs 
regulate lung-specific genes with immunomodulatory functions, such as Sftpa1 (coding 
for SP-A) and Scgb1a1 [93]. This furthermore implies that the regulation of target 
genes by C/EBPs is cell and tissue specific, as previously proposed [91].  
 
Possible mechanisms of LPS stimulation in bronchial epithelial cells  
The activity level of C/EBPβ is increased by LPS stimulation in extra-pulmonary cells 
[299]. In addition, other inflammatory stimuli, such as TNFα induce C/EBPβ 
transactivation in bronchial epithelial cells [236]. Current evidence, however, suggests 
that the activity of C/EBP in bronchial epithelial cells is unaffected by LPS stimulation 
in vitro [128]. The results presented in paper IV further support the idea that LPS 
stimulation fails to significantly induce C/EBP transactivation immediately, although a 
trend towards increased activity was observed (p=0.097). The limited induction of 
C/EBP transactivation following LPS stimulation may be related to the low expression 
of the major LPS receptor TLR4 in BEAS-2B cells [300]. With this in mind, it is 
advisable that further studies address this in primary cells, such as NBEC. It is, 
however, also conceivable that other mechanisms than increased transcriptional 
activation, such as the total level of C/EBP proteins or the C/EBPβ LIP/LAP ratio, and 
may be important following LPS stimulation of airway epithelial cells. These 
mechanisms are probably slower than induction of transactivation and could take 
longer than the 1 hour time point studied in vitro. Immune responses to respiratory 
pathogens in the lung are mediated by a complex interaction between epithelial and 
inflammatory cells, that may be difficult to mimic in vitro [301]. While epithelial cells 
sense the presence of microorganisms and actively recruit inflammatory cells, the 
secondary response is dependent on the activation of epithelial cells by infiltrating 
inflammatory cells [76], which is difficult to model in vitro. An example of this is the 
LPS-induced expression of GROα that, in Clara cells, is enhanced by macrophage 
derived TNFα [302]. Thus, in vitro studies investigating the individual response of a 
single cell population to an inflammatory stimulus may reveal intriguing functions of 
cells within the lung, although the picture is incomplete.  
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Impaired C/EBPβ signaling may weaken pulmonary host defenses 
The involvement of C/EBPβ in LPS-induced respiratory neutrophilia suggests that this 
transcription factor may play an essential role in the innate immune responses to 
bacterial infections. Reduced C/EBPβ activity in smokers with COPD [94] may 
attenuate innate immune responses and predispose the lungs to reoccurring bacterial 
infections or permanent microbial colonization, as observed among COPD patients 
[303], since neutrophils are central in bacterial elimination [304]. The consequence of 
reduced neutrophilia could, however, also be beneficial, as persistent neutrophil influx 
has been suggested to contribute to the pathogenesis of COPD [304]. Although LPS 
induces a strong inflammatory response in the airways, its similarity to actual infections 
is limited since bacteria are recognized by several PRRs. To definitively conclude that 
lung epithelial C/EBPβ plays a role in bacterial infection, it is therefore necessary to 
infect mice with live bacteria and assess the immune responses in the lung (further 
discussed in the Future Perspectives section).  
 
 
4.4 C/EBP CONTRIBUTES TO THE EFFECTS OF LONG-ACTING 2-
AGONISTS AND GLUCOCORTICOIDS 
 
The LPS model of pulmonary neutrophilia also allows for investigations of the 
involvement of C/EBPβ in pharmacological suppression of inflammatory responses. 
Thus, in paper IV, the role of C/EBPβ in simultaneous LPS challenge and LABA 
and/or GC treatment was investigated in paper IV. 
 
β2-adrenergic agonists have been suggested to activate C/EBPα in vitro [231, 232], and 
C/EBPα is important for the effects of GCs on proliferation and differentiation in 
several cell types [92], including bronchial smooth muscle cells [129, 305]. The 
binding activity of C/EBPβ is increased by GCs in bronchial epithelial cells [133],  
possibly explaining the ability of GCs to enhance expression of host defense molecules 
[40], since functional GREs are absent in the promoters of some lung-specific, GC-
induced genes [132, 133]. The role of C/EBPβ in the suppression of inflammatory 
genes by LABAs and GCs has not been addressed, and it is presently not known 
whether LABAs activate C/EBPs in the airway epithelium. This is particularly 
intriguing considering that C/EBPβ contributes to the regulation of many genes coding 
for cytokines and chemokines following inflammatory stimuli [90, 91, 93, 306, 307], 
implying that C/EBPβ may be influenced by both inflammatory and anti-inflammatory 
signaling.  
 
 
4.4.1 C/EBPβ mediates the suppressive action of formoterol on 
inflammatory signaling 
 
To assess the role of C/EBPβ in mediating the effects of LABAs and GCs in the lung 
epithelium, Cebpb∆LE and Cebpbfl/fl mice were pre-treated with a LABA, formoterol 
(FM), a GC, budesonide (BUD), or FM together with BUD, and subsequently 
challenged with aerosolized Ps. aeruginosa LPS. As demonstrated in paper IV, the 
suppressive effects of FM on neutrophil infiltration along with inflammatory mediator 
expression were impaired in CebpbΔLE mice. Furthermore, FM significantly increased 
expression of LPS-induced Groa and Il6 in CebpbΔLE mice but not in Cebpbfl/fl mice. 
The blunted suppression of Groa and Il6 by combination treatment with FM and BUD, 
observed in CebpbΔLE mice, may consequently be related to the stimulatory effect of 
FM alone in these mice. As mentioned previously, GROα is an important neutrophil 
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attractant [297, 298] and is implicated in COPD [169]. IL-6 has been suggested as a 
target for the medical therapy of COPD, on account of the amplifying function of this 
cytokine, which acts upstream of other inflammatory mediators [163]. The stimulation 
of these inflammatory mediators in CebpbΔLE mice indicates an inhibitory role of 
C/EBPβ in LABA signaling. 
 
In order to investigate the possible mechanisms by which LABAs such as FM affect 
C/EBP signaling, human bronchial epithelial cells (BEAS-2B) transfected with a 
C/EBP-luciferase reporter construct were stimulated with FM and LPS, FM with or 
without propranolol, or to forskolin. C/EBP transactivation was significantly induced 
by FM treatment with or without LPS, and the effect was reversed by pre-treatment 
with the β-adrenoceptor agonist propranolol. This demonstrates that the effect of FM on 
C/EBP activity is mediated by β-adrenoceptors, most probably the β2-adrenoceptor 
given that FM specifically activates this receptor. The similar stimulation of C/EBP 
transactivation by FM with LPS and by FM alone suggests that the mechanism by 
which FM stimulates C/EBP activity is the same at baseline and in the presence of an 
inflammatory stimulus. The cAMP elevating agent forskolin also significantly 
increased C/EBP dependent transactivation, further indicating that the β2-adrenoceptor 
dependent activation of C/EBPs by FM may involve cAMP signaling. In summary, FM 
putatively stimulates C/EBP transactivation via the β2-adrenoceptor and cAMP in 
bronchial epithelial cells in vitro, suggesting that the inflammatory suppression by FM 
observed in vivo is mediated by increased C/EBPβ activity. Overall, these findings 
demonstrate a key role for lung epithelial C/EBPβ in the suppression of inflammatory 
mediators implicated in COPD by LABAs, which are frequently used in COPD 
therapy.   
 
 
4.4.2 A role for C/EBPβ in mediating glucocorticoid suppression of 
inflammatory mediators 
 
The results presented in paper IV also support a role for C/EBPβ in mediating the 
suppressive effects of GCs in the airway epithelium. Significantly blunted suppression 
of LPS-induced Il6 and Cox2 expression by BUD was observed in LPS-challenged 
Cebpb∆LE mice. COX-2 is involved in the synthesis of prostanoids from arachidonic 
acid, with a key role in inflammatory signaling in lung disease [308]. Upon GC 
treatment, C/EBPβ has been demonstrated to physically interact with the GR and bind 
to the Cox2 promoter [309]. In addition to the differences in Il6 and Cox2 expression 
observed in LPS-challenged Cebpb∆LE mice, the suppression by BUD with FM of base-
line Tnfa expression in naïve, unchallenged Cebpb∆LE mice was significantly blunted, 
and, similarly, a trend towards blunted suppression was observed with BUD alone 
(p=0.095), compared to Cebpbfl/fl mice. As mentioned earlier, TNFα is implicated in 
COPD pathogenesis and effective suppression of this cytokine is suggestively central in 
COPD management. Also, impaired suppression of baseline Nos2 expression (coding 
for inducible nitric oxide synthase, iNOS) was observed in Cebpb∆LE mice. NOS 
enzymes expressed in the airway epithelium generate endogenous nitric oxide (NO) by 
converting L-arginine to L-citrulline, and both exhaled NO and iNOS are elevated in 
COPD [171, 310]. Taken together, these findings complement the previously observed 
involvement of C/EBPβ in the sparing or enhancement of host defense molecules by 
GCs [40] with additional evidence of a role for C/EBPβ in the suppression of 
inflammatory mediators by GCs, possibly by the previously described mechanism of 
increased C/EBPβ activity by GC stimulation. In agreement with the previous in vitro 
documentation by Zhang and colleagues [40], the acute phase reactant Saa3 appeared 
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to be stimulated by GCs only in LPS-challenged Cebpbfl/fl mice, with no effect 
observed in Cebpb∆LE mice. As demonstrated by others, C/EBPβ and GR 
synergistically enhance the transcription of the host defense gene Orm1 (coding for α1-
glycoprotein) by binding to overlapping sites in the promoter [311, 312], providing a 
possible mechanism that could serve to explain the GC stimulation of Saa3. Taken 
together with the blunted suppression of inflammatory mediators, these findings 
suggest that impaired C/EBPβ signaling in smokers with or without COPD [94, 313] 
and reduced C/EBPδ expression in the bronchial smooth muscle cells of COPD patients 
[314] may represent an additional and novel mechanism that may partly explain the 
relative GC resistance in COPD. 
 
 
4.4.3 Possible mechanisms of C/EBPβ as a mediator of simultaneous 
inflammatory and anti-inflammatory signaling 
 
The potential involvement of C/EBPβ in mediating both LPS-induced inflammation as 
well as the anti-inflammatory effects of LABAs and GCs are individually supported by 
previous in vitro studies [40, 90, 132, 133, 232], although the mechanism underlying 
this divergent action is still unknown. A possible explanation is provided by different 
post-transcriptional modifications such as phosphorylation, SUMOylation and 
acetylation, which have been demonstrated to affect the activity of C/EBPβ [91, 315-
317]. C/EBPβ is the only C/EBP family member that contains additional and unique 
regions that are targets for post-transcriptional modifications [86]. It has previously 
been shown that SUMOylation of C/EBPβ represses Cox2 transcription [318], as 
opposed to the other documented role of C/EBPβ in promoting transcription of Cox2 
[319]. This represents an interesting mechanism by which the function of C/EBPβ 
could be altered from inflammatory to anti-inflammatory by affecting DNA-binding 
activity and specificity dependent on post-transcriptional modification. Phosphorylation 
of amino acid residues on C/EBPβ is an important determinant of transactivation and is 
required for the induction of pro-inflammatory genes. Multiple phosphorylation sites 
have also been documented [86], implying that different signaling pathways converge 
and influence the activity of C/EBPβ. Some of these post-transcriptional modifications 
are likely to direct C/EBPβ to bind negative regulatory DNA sequences, thereby 
inhibiting gene transcription of inflammatory genes [320, 321], as opposed to 
stimulating transcription of pro-inflammatory genes. It is also plausible that GCs and 
LABAs stimulate the translation of LIP, which could inhibit the expression of pro-
inflammatory genes. In addition, C/EBPβ contains negative regulatory regions in the N-
terminus, which could be involved in the shift from inflammatory to anti-inflammatory 
signaling, although the precise role of these regions is unknown [91].  
 
The ability of C/EBPs to physically interact with different proteins [227, 322, 323] and 
consequently bind to different DNA sequences is well-documented [323, 324]. It is 
theoretically possible that inflammatory and anti-inflammatory stimuli differentially 
influence this capacity by inducing different post-transcriptional modifications on 
C/EBPs or other proteins (Figure 11 A and B). In support of a role for this mechanism, 
LPS has been reported to increase IL1B transcription via binding of C/EBPβ and 
activating transcription factor (ATF)4 to an enhancer segment of the gene. On the other 
hand, when cAMP response element-binding (CREB) is phosphorylated as a 
consequence of cAMP stimulation, CREB dimerizes with C/EBPβ and compete for 
binding to the enhancer sequence, with suppression of the LPS-induced response [86]. 
C/EBPs could accordingly be targeted to certain gene promoters, depending on protein-
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protein interactions with other transcription factors. Another mechanism that could 
explain the involvement of C/EBPβ in GC signaling involves the mitogen-activated 
protein kinase (MAPK)-phosphatase (MKP)1/dual specificity phosphatase (DUSP)1, 
which reduces pro-inflammatory signaling by inhibiting MAPKs such as extracellular 
signaling-regulated kinase (ERK) and p38 [325-330]. Although DUSP1 is induced by 
GCs, C/EBP binding sites, not GREs are necessary for transcription of the gene [331] 
and transactivation has been proposed to involve a tethering mechanism with GR and 
C/EBPβ bound to the promoter [331]. This implies that C/EBPβ may mediate the anti-
inflammatory effects of GC by inducing DUSP1, possibly effecting GC suppression of 
inflammatory mediators such as COX-2 and IL-6 through inhibition of MAPKs. In 
summary, C/EBPβ could mediate both the pro-inflammatory induction as well as the 
immune suppressive effects of GCs and LABAs, although the mechanism explaining 
this dual action is still unknown. 
 
 
 
 
Figure 11. A proposed model for the dual role of C/EBPβ in contributing to the inhibition and 
induction of inflammatory responses. (A) Inflammatory signaling induces post-transcriptional 
modifications that activate C/EBPβ, which homodimerizes, binds to C/EBP-responsive elements and 
stimulates transcription of pro-inflammatory genes. (B) Anti-inflammatory stimuli induce other post-
transcriptional modifications that direct C/EBPβ dimerization with other proteins and binding to 
negative regulatory DNA sequences, which inhibits gene transcription. 
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4.5 PRELIMINARY RESULTS 
 
4.5.1 The role of lung epithelial-C/EBPβ in influenza infection 
 
Influenza A is a common respiratory virus that causes significant morbidity and 
mortality world-wide, and influenza infection is associated with COPD exacerbations 
[290, 291, 332]. Influenza infection induces C/EBP activity in the murine lung [333]; 
however, the role of C/EBPβ in respiratory viral infections remains unknown. With the 
objective of elucidating whether C/EBPβ promotes inflammatory responses to 
influenza infection, the inflammatory mediator response to dsRNA stimulation was 
analyzed in human NCI-H292 airway epithelial cells with siRNA-inhibited expression 
of C/EBPβ, and in precision cut lung slices (PCLS) from CebpbΔLE mice. CebpbΔLE 
mice were also used to examine the inflammatory response to H1N1 Influenza A 
infection in vivo, as well as ex vivo in PCLS.  
 
The studies performed so far have revealed that dsRNA induces the expression of 
CEBPB in NCI-H292 cells, while inhibition of CEBPB in these cells causes disrupted 
dsRNA-induced expression of cytokines and chemokines. In our study, influenza 
infection resulted in respiratory neutrophilia, the induction of inflammatory mediators 
and, in agreement with the previously observed induction of C/EBP activity [333], 
increased pulmonary expression of Cebpb. Also, influenza-infected Cebpb∆LE mice 
demonstrated a delayed onset of clinical symptoms and decline in body weight as well 
as increased expression of Tnfa, Il1b, and Mip1g, compared to infected wild-type 
controls. The expression of the host defense genes Scgb1a1 and Sftpa1 was, however, 
lower in Cebpb∆LE mice as compared to Cebpbfl/fl mice. In the immediate-early 
inflammatory response, assessed in PCLS from Cebpbfl/fl and CebpbΔLE mice, blunted 
cytokine and chemokine induction in response to both dsRNA stimulation and 
influenza infection was observed in PCLS from CebpbΔLE mice, compared to PCLS 
from wild-type mice. Thus, lung epithelial-C/EBPβ appears to be a mediator of the 
immediate-early induction of innate immune responses to influenza infection, and may 
hence play a role in influenza virus-induced COPD exacerbations. Further studies are 
warranted to investigate the impaired innate immune responses in vivo, and to 
determine the long-term outcome of C/EBPβ deletion for influenza infection, with 
regard to clinical presentation, viral titers, and survival.  
 
 
4.6 CONCLUDING REMARKS 
 
The results presented herein collectively demonstrate that C/EBPs play pivotal roles in 
epithelial cell differentiation during lung organogenesis, and that both C/EBPα and 
C/EBPβ are involved in pathological processes related to COPD with an important role 
for C/EBPβ in inflammatory responses. In addition, the findings presented in this thesis 
indicate a key role for the airway epithelium in inflammatory responses in the lung.  
 
The development of histopathology similar to COPD in adult CebpaΔLE mice suggests 
that lung immaturity at birth contributes to lung pathology in the adult. Although 
several studies support an increase in airway symptoms and obstruction among children 
and adolescents who were delivered prematurely [136, 140, 266-269], the outcome for 
the development of respiratory disorders later in life is still unknown. This warrants 
large epidemiological studies of the prevalence of airway obstruction among adults that 
were prematurely delivered, as these individuals grow older. This is particularly 
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important since improved critical care has led to increased survival of extremely 
premature infants with severely immature lungs.  
 
The findings in paper II suggest that C/EBPα and C/EBPβ are required for airway 
epithelial differentiation. The ectopic mucus producing cells observed in mice lacking 
C/EBPβ and/or C/EBPα furthermore suggest that C/EBPs may play a part in airway 
remodeling, with implications in both COPD and asthma. Moreover, evidence suggests 
that functional replacement of C/EBPβ by other lung-enriched C/EBPs, for instance 
C/EBPα, as well as additional compensatory mechanisms involving other pro-
inflammatory transcription factors, may mask the actual role of C/EBPβ in the lung 
epithelium. However, these mechanisms may be ineffective following inflammatory 
stimuli, such as cigarette smoke exposure or LPS challenge, when other C/EBPs appear 
to have a limited ability to compensate for C/EBPβ. These results are of particular 
interest considering the reduced activity of C/EBPβ in the airway epithelium of 
smokers with COPD [94], and implies that other lung-enriched C/EBPs with preserved 
expression may not compensate for impaired C/EBPβ activity when lung sterility is 
compromised, such as during respiratory infection. Further studies in infection models 
are thus needed to investigate these proposed mechanisms.  
 
The results in paper III and IV demonstrate a blunted inflammatory response to LPS as 
well as cigarette smoke in CebpbΔLE mice, and suggest that C/EBPβ is a pro-
inflammatory transcription factor in the lung epithelium. In vivo as well as in vitro 
evidence also points towards a role for C/EBPβ in mediating the suppressive effects on 
inflammation of LABAs and GCs in the pulmonary epithelium, suggesting that 
C/EBPβ may be involved in suppressing inflammatory signaling under some 
circumstances. Inflammatory responses to cigarette smoke are observed both in COPD 
patients and asymptomatic smokers [163, 334]. As asymptomatic smokers exhibit 
markedly increased activity of C/EBPβ, while smokers with COPD display decreased 
C/EBPβ activity [94], C/EBPβ may contribute to the inflammatory response among 
asymptomatic smokers, while other inflammatory transcription factors may be more 
central in driving exaggerated inflammatory signaling in COPD [335, 336]. The role of 
C/EBPβ in chronic inflammation has, however, not been investigated. It is also possible 
that the impaired C/EBPβ signaling among smokers with COPD impairs host defenses 
to respiratory pathogens and increased apoptosis [91, 93], although this remains to be 
addressed. C/EBPβ signaling may thus also be relevant in other inflammatory lung 
disorders associated with, or exacerbated by, pathogens, such as asthma. In addition, 
C/EBPs have been demonstrated to activate anti-oxidative defenses [337, 338], and 
decreased C/EBPβ activity could result in increased epithelial damage by oxidative 
stress. In light of this, additional studies investigating the contribution of C/EBPβ to 
host defenses in a model using both cigarette smoke exposure and a respiratory 
pathogen is crucial to increase our understanding of C/EBP transcription factors in the 
lung epithelium further.  
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5 FUTURE PERSPECTIVES 
 
Since COPD is a complex and multifactorial disease with both environmental and 
genetic contributions, further studies more closely investigating the role of C/EBPs in 
disease pathogenesis is warranted. While the studies in this thesis demonstrate that lung 
epithelial C/EBPβ plays a role in smoke-induced lung inflammation as well as 
pathogen-related signaling associated with COPD, the relevance of this in COPD 
pathogenesis needs to be addressed further. From the results presented in this thesis, 
future investigations should target three central components of COPD; 1) cigarette 
smoke and pathogen-induced lung inflammation, 2) airway remodeling and 3) 
exacerbated responses to microbial infection. These pre-clinical studies could translate 
to translational and clinical research and have the potential to improve the quality of 
life of millions of patients who suffer from COPD. 
 
The involvement of C/EBPβ in inflammatory responses to long-term cigarette smoke 
exposure has thus far not been addressed. The findings of impaired acute and sub-acute 
inflammatory responses to cigarette smoke in mice lacking C/EBPβ presented in this 
thesis suggest that impaired C/EBPβ signaling may protect against emphysema. In vivo 
investigations into this are required, as the effect of C/EBPβ deletion on chronic 
cigarette smoke exposure may differ from the observed effect of acute or sub-acute 
smoke exposure. Such studies would enable the assessment of the degree of airway and 
pulmonary inflammation as well as emphysematous changes in the lung parenchyma of 
mice lacking C/EBPβ specifically in the lung epithelium. Moreover, the mechanism by 
which C/EBPβ contributes to cigarette smoke-induced airway inflammation has not 
been addressed in detail, and further investigations may reveal mechanisms with the 
potential to enhance our understanding of the detrimental effects of cigarette smoke. In 
addition, the involvement of C/EBPs in host defenses to respiratory pathogens is 
important to investigate. COPD exacerbations drive disease progression, account for a 
large portion of the morbidity and mortality associated with the disease, and place a 
significant burden on the health care system. Efforts must therefore be made to 
minimize the damaging effects of respiratory infections in pulmonary disorders. 
 
As C/EBPβ is implicated in COPD and respiratory infections cause COPD 
exacerbations, the role of C/EBPβ in innate immune responses and epithelial 
regeneration following respiratory infection may be central to understanding COPD 
pathogenesis. To address this, we have so far focused on the inflammatory responses to 
Influenza A and Haemophilus influenzae. Preliminary data shows an impaired 
activation of innate immune responses observed in precision cut lung slices in the initial 
phase of influenza infection in CebpbΔLE mice, while the responses to influenza A and 
H. influenzae are preserved or elevated 5 days and 12 hours after infection, 
respectively, in these mice. There is also evidence of airway remodeling in influenza-
infected CebpbΔLE mice. Additional studies will focus on the immediate-early 
inflammatory responses as well as infection-induced epithelial differentiation. Since 
cigarette smoke compromises antimicrobal host defenses [162], a model encompassing 
cigarette smoke exposure with concomitant bacterial or viral infection, which 
recapitulates many of the features of COPD exacerbations [294, 339], is also warranted. 
This is of particular interest as exacerbations are central to driving COPD progression, 
with each individual exacerbation causing deterioration in lung function that does not 
fully recover [143, 154]. Models with both cigarette smoke challenge and viral or 
bacterial infection better mimics the pulmonary insult of chronic lung disease [248, 
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294, 295, 339, 340] and provides a suitable model to investigate the role of C/EBPs in 
exacerbations of inflammatory lung diseases. Following completion of a research 
program as outlined above, we will have a better understanding of the processes that 
drive the progression of airway disorders. The outcome of future studies has possible 
implications for future therapies of infection-induced COPD and asthma exacerbations, 
and may help to prevent disease progression.  
 
The inflammatory response to respiratory infections can be effectively studied in 
cigarette smoke-exposed mice using precision cut lung slices. This ex vivo model 
allows for assessment of the responses of the structural cells of the lung, but fails to 
completely replace in vivo studies, as cells of the circulatory system (i.e. immune cells) 
have a large impact on the outcome. In order to investigate the role of C/EBPβ in an 
exacerbation model, mice will be exposed to cigarette smoke and precision cut lung 
slices from these mice will be infected with influenza A to determine the time course of 
the inflammatory response in cells with or without C/EBPβ. In vivo studies will 
subsequently investigate the inflammatory response in detail, at selected time points. It 
has furthermore been suggested that a failure to repair damaged tissue plays a role in 
the pathogenesis of emphysema [148]. Considering that C/EBPβ may be involved in 
regulating proliferation in the lung epithelium (unpublished observations), and could 
amplify inflammatory responses, suppression of C/EBPβ may be beneficial and protect 
against emphysema. In further support of this, many of the genes that exhibited blunted 
induction in challenged CebpbΔLE mice (i.e. Groa, Il1b, Tnfa and Il6) contribute to or 
are associated with the development of emphysema. It is thus possible that CebpbΔLE 
mice show attenuated emphysema. Assessment of the role of C/EBPβ in GC and 
LABA signaling would also be of interest in a model with both cigarette smoke 
exposure and respiratory infection, since such a challenge has been suggested as a 
model for COPD exacerbation [339], and maintenance treatment with GCs together 
with LABAs are used to reduce the frequency and severity of COPD exacerbations.  
 
The ultimate goal of all these studies is, of course, to improve the quality of life of 
patients suffering from inflammatory lung disorders. Further advancements in our 
understanding of transcriptional regulation of inflammatory signaling and 
differentiation programs may lead to the discovery of new potential targets for 
pharmacological interventions. The signaling pathways that involve C/EBPβ are of 
great interest in this context and future investigations have the potential to provide 
important clues to inflammatory signaling pathways and epithelial differentiation. 
Repression of C/EBPβ may suppress the chronic inflammation observed in pulmonary 
disorders; however, this could also potentially impair host defenses to respiratory 
infections. Thus, the most optimal way to improve the clinical outcome of COPD by 
manipulating C/EBPβ signaling is possibly through precise mapping of post-
transcriptional modifications as well as interactions with other proteins, and accurate 
targeting of the signaling pathways that suppress amplifying cytokines such as IL-6 (i.e. 
chronic inflammation) while stimulating host defense molecules such as SCGB1A1 and 
surfactant proteins. Stimulation of such a pathway would most probably be achieved by 
activating kinases that phosphorylate C/EBPβ. It is, however, necessary to considerably 
advance the understanding of the precise role of C/EBPs in lung homeostasis and 
inflammatory responses before such ambitious studies are initiated.    
 
The adult phenotype of CebpaΔLE; CebpbΔLE mice still remains unknown. 
Compromised epithelial cell differentiation in these mice supports further 
investigations to address the outcome of Cebpa and Cebpb deletion in the adult lung. 
These studies would be possible to do using inducible Cre (i.e. the Tet-ON system) 
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with Cebpa and Cebpb deleted in adult lungs to circumvent lethality at birth due to 
respiratory failure. Utilizing inducible Cre, airway remodeling as well as the 
inflammatory response to long-term cigarette smoke exposure (i.e. emphysema) may 
also be addressed in CebpaΔLE mice and CebpaΔLE; CebpbΔLE mice. This may reveal 
interesting clues to the pathology of the airways, as this thesis has provided evidence 
that epithelial integrity as well as the differentiation of facultative progenitor cells is 
impaired in CebpaΔLE; CebpbΔLE mice.  
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